As
Filed Pursuant to Rule 424(b)(5)
Registration
No. 333-267236
PROSPECTUS
SUPPLEMENT
(To Prospectus and Prospectus Supplement dated September 9, 2022)
INDAPTUS
THERAPEUTICS, INC.
Up
to $3,717,317.70 of Common Stock
This
Prospectus Supplement supplements the prospectus and the prospectus supplement, each dated September 9, 2022 (together,
the “ATM Prospectus”), relating to the offer and sale of shares of our common stock having an aggregate offering price
of up to $6,300,000 pursuant to the terms of the At The Market Offering Agreement, dated June 1, 2022, as amended on September
1, 2022 (the “Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”). Through the date hereof, we
have not sold any shares of our common stock through Wainwright under the Agreement. This Prospectus Supplement should be read in conjunction
with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes
the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized
in connection with, the ATM Prospectus, and any future amendments or supplements thereto.
On
March 17, 2023, the date we filed our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, we became subject to the
offering limits in General Instruction I.B.6 of Form S-3. As of the date of this Prospectus Supplement, the aggregate market value of
our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $11,151,953.10, which was calculated
based on 5,869,449 shares of our outstanding common stock held by non-affiliates and a price of $1.90 per share, the closing price
of our common stock on March 24, 2023, which is the highest closing sale price of our common stock on the Nasdaq Capital Market
within the prior 60 days. As of the date of this Prospectus Supplement, we have not sold any securities pursuant to General Instruction
I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this Prospectus Supplement. Pursuant to General
Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third
of our public float (as defined by General Instruction I.B.6) in any 12 calendar month period so long as our public float remains below
$75.0 million.
We
are filing this Prospectus Supplement to amend the ATM Prospectus to reflect the limitations on the maximum amount of shares
that we are eligible to sell under General Instruction I.B.6. As a result of these limitations, we may currently only offer and sell
shares of our common stock having an aggregate offering price of up to $3,717,317.70 pursuant to the Agreement. However, in the
event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to
one-third of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement.
In the event that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6
of Form S-3. If our public float increases such that we may sell additional amounts under the Agreement and the registration statement
of which this Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to
making additional sales.
Our common
stock trades on the Nasdaq Capital Market under the symbol “INDP.” On March 24, 2023, the last reported sale price
of our common stock on the Nasdaq Capital Market was $1.90 per share.
In
addition, the paragraph under “LEGAL MATTERS” on page S-10 of the ATM Prospectus is replaced in its entirety with the
following: “Latham & Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities
offered hereby on behalf of Indaptus Therapeutics, Inc. Haynes and Boone, LLP, New York, New York is counsel for Wainwright in
connection with this offering.”
INVESTING
IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE S-4 OF THE ATM PROSPECTUS AND IN THE DOCUMENTS
INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal
offense.
H.C. Wainwright & Co.
The
date of this prospectus supplement is March 27, 2023.
PROSPECTUS
SUPPLEMENT
(To
Prospectus dated September 9, 2022)
INDAPTUS
THERAPEUTICS, INC.
Up
to $6,300,000
Shares
of Common Stock
We
have entered into an at-the-market offering agreement, or the Offering Agreement, dated June 1, 2022, as amended, with H.C. Wainwright
& Co., LLC, or the Sales Agent or Wainwright, as sales agent relating to the shares of our common stock, par value $0.01 per share,
offered by this prospectus supplement. In accordance with the terms of the Offering Agreement, we may offer and sell shares of our common
stock having an aggregate offering price of up to $6.3 million from time to time through Wainwright acting as our sales agent.
Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in transactions that are deemed
to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act,
including sales made directly on or through The Nasdaq Capital Market, or Nasdaq, the existing trading market for our common stock, or
any other existing trading market in the Unites States for our shares of common stock, sales made to or through a market maker other
than on an exchange or otherwise, directly to the Sales Agent as principal, in negotiated transactions at market prices prevailing at
the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted by law. If we and Wainwright
agree on any method of distribution other than sales of our common stock into Nasdaq or another existing trading market in the United
States at market prices, we will file an additional prospectus supplement providing all information about such offering as required by
Rule 424(b) under the Securities Act. Wainwright is not required to sell any specific amount, but will act as our sales agent using commercially
reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow,
trust or similar arrangement.
We
will pay Wainwright a commission equal to 3.0% of the gross sales price per share of common stock issued by us and sold through it as
Sales Agent. In connection with the sale of the shares of common stock on our behalf, Wainwright will be deemed to be an “underwriter”
within the meaning of the Securities Act, and the compensation of Wainwright will be deemed to be underwriting commissions or discounts.
Our
shares of common stock are traded on the Nasdaq Capital Market under the symbol “INDP.” The last reported sale price of our
shares of common stock, as reported on the Nasdaq Capital Market on August 31, 2022 was $2.52.
The
aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was $19,171,306,
which was calculated based on 8,258,597 shares of common stock outstanding, as of August
31, 2022, of which 5,757,149 shares were held by non-affiliates, and a price per share of $3.33 which was the closing sale price of our
common stock on the Nasdaq Capital Market on August 5, 2022. We have not offered any securities pursuant to General Instruction I.B.6
of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
Investing
in our shares of common stock involves risks. See the section entitled “Risk Factors” beginning on page S-4 of this prospectus
supplement and in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement and the accompanying prospectus. Any representation to the contrary is a
criminal offense.
H.C.
Wainwright & Co.
The
date of this prospectus is September 9, 2022
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS SUPPLEMENT
This
prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the Securities and Exchange
Commission, or SEC, utilizing a “shelf” registration process. This document is in two parts. The first part is the prospectus
supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, including the documents
incorporated by reference into the accompanying prospectus, which provides more general information about securities we may offer from
time to time, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts
of this document combined. We urge you to carefully read this prospectus supplement and the prospectus, and the documents incorporated
by reference herein and therein, before buying any of the securities being offered under this prospectus supplement. This prospectus
supplement may add or update information contained in the prospectus and the documents incorporated by reference therein. To the extent
that any statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents
incorporated by reference therein that were filed before the date of this prospectus supplement, the statements made in this prospectus
supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference
therein. If any statement in one of these documents is inconsistent with a statement in another document having a later date –
for example, a document incorporated by reference in the accompanying prospectus – the statement in the document having the later
date modifies or supersedes the earlier statement.
You
should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus,
or contained in any free writing prospectus prepared by us or on our behalf. We have not, and Wainwright has not, authorized anyone to
provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it.
The distribution of this prospectus supplement and sale of these securities in certain jurisdictions may be restricted by law. We are
not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Persons in possession of this
prospectus supplement or the accompanying prospectus are required to inform themselves about and observe any such restrictions. The information
contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement
and the accompanying prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering,
is accurate only as of the date of those respective documents regardless of the time of delivery of this prospectus supplement or the
accompanying prospectus or when any sale of our shares of common stock occurs. Our business, financial condition, results of operations
and prospects may have changed since those dates.
You
should read this prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement
and the accompanying prospectus, in their entirety, before making an investment decision. You should also read and consider the information
in the documents to which we have referred you in the sections of this prospectus supplement entitled “Where You Can Find More
Information” and “Incorporation of Certain Documents by Reference.”
This
prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described
herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety
by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein
by reference as exhibits to the registration statement, and you may obtain copies of those documents as described below under the section
entitled “Where You Can Find More Information.”
We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or
covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.
This
prospectus supplement incorporates by reference market data and certain industry data and forecasts that were obtained from market research
databases, consultant surveys commissioned by us, publicly available information, reports of governmental agencies and industry publications
and surveys. Industry surveys, publications, consultant surveys commissioned by us and forecasts generally state that the information
contained therein has been obtained from sources believed to be reliable. We have relied on certain data from third-party sources, including
internal surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of
the industry. Statements as to our market position are based on the most currently available data. While we are not aware of any misstatements
regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change
based on various factors, including those discussed under the heading “Risk Factors” in this prospectus, and under similar
headings in the other documents that are incorporated herein by reference.
Certain
figures included in this prospectus supplement have been subject to rounding adjustments. Accordingly, figures shown as totals in certain
tables may not be an arithmetic aggregation of the figures that precede them.
All
references to “we,” “us,” “our,” “Indaptus Therapeutics”, “Indaptus”, “the
Company” and “our company”, in this prospectus are to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.) and,
where appropriate, its consolidated subsidiaries Intec Pharma Ltd. and Decoy Biosystems, Inc. References to “Intec Parent”
refer to Intec Parent, Inc., the successor of Intec Pharma Ltd. following the Domestication Merger, references to “Intec Israel”
refer to Intec Pharma Ltd., the predecessor of Indaptus prior to the Domestication Merger, and references to “Decoy” refer
to Decoy Biosystems, Inc., the entity acquired by Indaptus in connection with the Merger described elsewhere in this prospectus.
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights
certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus
supplement. This summary is not complete and does not contain all of the information that you should consider before deciding
whether to invest in our shares of common stock. For a more complete understanding of our company and this offering, we encourage you
to read and consider carefully the more detailed information in this prospectus supplement, including the information incorporated
by reference in this prospectus supplement, and the information included in any free writing prospectus that we have authorized
for use in connection with this offering, including the information under the heading “Risk Factors” in this prospectus supplement
on page S-4.
Our
Company
We
are a pre-clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
Our technology has evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient
activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted
package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single
strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability
to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral
activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint
therapy, targeted antibody therapy and low-dose chemotherapy in pre-clinical models. Tumor eradication by our technology has demonstrated
activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen
in pre-clinical models. We have carried out successful GMP manufacturing of our lead clinical candidate, Decoy20, and completed other
IND-enabling studies.
Unlike
many competitor products, our technology does not depend on targeting with or to a specific antigen, providing broad applicability across
multiple indications. Our product candidates are designed to have a much shorter half-life and produce less systemic exposure than small
molecule, antibody or human cell-based therapies, potentially reducing the risk of non-specific auto-immune reactions. Our technology
produces single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal and pancreatic
tumors and has also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency
virus (HIV) infections in pre-clinical models. In May 2022, the U.S. Food and Drug Administration cleared our Investigational New Drug,
or IND, application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed
and plan to commence a Phase 1 clinical trial in the second half of 2022 targeting solid tumors. Target indications include, but not limited to, colorectal, hepatocellular (± HBV), bladder, cervical
and pancreatic carcinoma.
Corporate
Information
Our
principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019 and our telephone number is (646) 427-2727. Our website address is http://www.indaptusrx.com. The information contained on, or that can be accessed through, our website
is neither a part of nor incorporated into this prospectus. We have included our website address in this prospectus solely as an inactive
textual reference.
THE
OFFERING
Common
stock to be offered by us
|
|
Our
shares of common stock having an aggregate offering price of up to $6.3 million. |
|
|
|
Shares
of common stock to be outstanding after this offering |
|
Up
to 10,758,597 shares of common stock (as more fully described in the notes following
this table), assuming sales of 2,500,000 shares of common stock in this offering at
an offering price of $2.52 per share, which was the last reported sale price of our
shares of common stock on the Nasdaq Capital Market on August 31, 2022. The actual number
of shares of common stock issued will vary depending on the sales price under this offering
at which shares may be sold from time to time during this offering.
|
|
|
|
Form
of Offering |
|
The
Sales Agent may, according to the terms of the Offering Agreement, sell the shares of our
common stock offered under this prospectus supplement from time to time in an “at-the-market”
offering. See “Plan of Distribution” on page S-9.
|
|
|
|
Use
of Proceeds |
|
We
currently intend to use the net proceeds from this offering to fund research and development
costs, including the conduct of one or more clinical trials and process development and manufacturing,
working capital and other general corporate purposes. Pending application of the net
proceeds for the purposes as described above, we may invest the net proceeds in short-term,
interest-bearing securities, investment grade securities, certificates of deposit or direct
or guaranteed obligations of the U.S. government. See “Use of Proceeds” on page
S-7.
|
|
|
|
Risk
Factors |
|
Investing
in our shares of common stock involves significant risks. See “Risk Factors”
on page S-4, and under similar headings in other documents incorporated by reference into
this prospectus.
|
|
|
|
Nasdaq
Capital Market symbol |
|
“INDP” |
Unless
otherwise indicated, the number of shares of common stock to be outstanding after this offering is based on 8,258,597
shares of common stock outstanding as of August 31, 2022 and excludes as of such date: (i) 1,613,123 shares of common stock issuable
upon exercise of outstanding options under our Indaptus 2021 Stock Incentive Plan, or the 2021 Plan, at a weighted exercise price of
$13.56, (ii) 374,244 shares of common stock reserved for potential future issuance pursuant to our 2021 Plan, and (iii) 3,090,787 shares
of common stock issuable upon the exercise of warrants outstanding at a weighted exercise price of $12.50 per share.
RISK
FACTORS
Investing
in our shares of common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the
risks described below and in our Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K incorporated by reference in this prospectus supplement and the accompanying prospectus, any amendment or
update thereto reflected in our subsequent filings with the SEC, and all of the other information in this prospectus supplement and the
accompanying prospectus, including our financial statements and related notes incorporated by reference in this prospectus supplement
and the accompanying prospectus. If any of these risks is realized, our business, financial condition, results of operations and prospects
could be materially and adversely affected. In that event, the trading price of our shares of common stock could decline and you could
lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may
also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.
Risks
Related to this Offering
We
will have broad discretion in how we use the net proceeds of this offering. We may not use these proceeds effectively, which could affect
our results of operations and cause our stock price to decline.
We
intend to use the net proceeds from this offering to fund our clinical trials, for working capital and for general corporate purposes.
Our management will have broad discretion over the use of proceeds from this offering, and we could spend the proceeds from this offering
in ways with which you may not agree or that do not yield a favorable return. Accordingly, you will be relying on the judgment of our
management with regard to the use of these net proceeds, and you will not have the opportunity as part of your investment decision to
assess whether the proceeds are being used appropriately. Our needs may change as the business and the industry that we address evolves.
It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return. The failure of our management
to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.
Purchasers in this offering may incur immediate
and substantial dilution in the book value of their investment as a result of this offering.
The
shares sold in this offering, if any, will be sold from time to time at various prices. The offering price per share in this offering
may exceed the net tangible book value per share. Therefore, if you purchase shares in this offering, your interest will be diluted to
the extent of the difference between the price per share you pay and the net tangible book value per share of common stock.
If
we raise additional capital in the future, your ownership in us could be diluted.
In
order to raise additional capital, we may at any time, including during this offering, offer additional shares of common stock or other
securities convertible into or exchangeable for our shares of common stock at prices that may not be the same as the price per share
in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share
paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
shareholders, including investors who purchase shares of common stock in this offering. The price per share at which we sell additional
shares of common stock or securities convertible into shares of common stock in future transactions may be higher or lower than the price
per share in this offering.
Until
such time, if ever, as we can generate substantial revenue from the sale of our products, we may finance our cash needs through a combination
of equity offerings, debt financings and license and development agreements. To the extent that we raise additional capital through the
further sale of equity securities or convertible debt securities, your ownership interest will be diluted, and the terms of these securities
may include liquidation or other preferences that adversely affect your rights as a shareholder.
Sales
of a substantial number of our shares of common stock in the public market could cause our stock price to fall.
We
may issue and sell additional shares of common stock in the public markets, including during this offering. As a result, a substantial
number of our shares of common stock may be sold in the public market. Sales of a substantial number of our shares of common stock in
the public markets, including during this offering, or the perception that such sales could occur, could depress the market price of
our shares of common stock and impair our ability to raise capital through the sale of additional equity securities.
There
has been and may continue to be significant volatility in the volume and price of our shares of common stock.
The
market price of our shares of common stock has been and may continue to be highly volatile. Factors, including timing, progress and results
of current and future preclinical studies and clinical trials and our research and development programs; regulatory matters, concerns
about our financial position, operations results, litigation, government regulation, developments or disputes relating to agreements,
patents or proprietary rights, and the COVID-19 pandemic and the ongoing conflict between Ukraine and Russia may have a significant impact
on the market volume and price of our stock. Unusual trading volume in our shares occurs from time to time.
The
shares offered hereby will be sold in “at-the-market” offerings, and investors who buy shares at different times will likely
pay different prices.
Investors
who purchase shares of common stock under this prospectus supplement at different times will likely pay different prices, and so may
experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices,
and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their
shares as a result of share sales made at prices lower than the prices they paid.
The
actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.
Subject
to certain limitations in the Offering Agreement and compliance with applicable law, we have the discretion to deliver a placement notice
to the Sales Agent at any time throughout the term of the Offering Agreement. The number of shares that are sold by the Sales Agent after
delivering a placement notice will fluctuate based on the market price of the shares of common stock during the sales period and limits
we set with the Sales Agent. Because the price per share of each share sold will fluctuate based on the market price of our shares of
common stock during the sales period, it is not possible at this stage to predict the number of shares that will ultimately be issued.
FORWARD-LOOKING
STATEMENTS
This
prospectus supplement, including the information incorporated by reference into this prospectus, contains, and any prospectus supplement
may contain statements that are forward-looking statements about our expectations, beliefs or intentions regarding, among other things,
our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. In addition,
from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,”
“plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,”
“target,” “will,” “project,” “forecast,” “continue” or their negatives or
variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters.
These forward-looking statements may be included in, among other things, various filings made by us with the SEC, press releases or oral
statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters
that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to
differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual
activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but
not limited to:
|
● |
our
plans to develop and potentially commercialize our technology; |
|
|
|
|
● |
the
timing and cost of our planned investigational new drug application and any clinical trials; |
|
|
|
|
● |
the
completion and receipt of favorable results in any clinical trials; |
|
|
|
|
● |
our
ability to obtain and maintain regulatory approval of any product candidate; |
|
|
|
|
● |
our
ability to protect and maintain our intellectual property and licensing arrangements; |
|
|
|
|
● |
our
ability to develop, manufacture and commercialize our product candidates; |
|
|
|
|
● |
the
risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation;
and |
|
|
|
|
● |
our
estimates regarding future revenue, expenses capital requirements and the need for additional financing. |
We
believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known
and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance
or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in
this prospectus supplement in greater detail under the heading “Risk Factors” and elsewhere in this prospectus. Given
these uncertainties, you should not rely upon forward-looking statements as predictions of future events.
All
forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified
in their entirety by the cautionary statements included in this prospectus. We undertake no obligations to update or revise forward-looking
statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except
as required by law. In evaluating forward-looking statements, you should consider these risks and uncertainties and not place undue reliance
on our forward-looking statements.
USE
OF PROCEEDS
The
amount of proceeds from this offering will depend upon the number of shares of common stock sold and the market price at which they are
sold. There can be no assurance that we will be able to sell any shares under or fully utilize the Offering Agreement with the Sales
Agent.
We
intend to use the net proceeds from the sale of the securities offered under this prospectus to fund our research and development costs,
including the conduct of one or more clinical trials and process development and manufacturing, working capital and other general corporate
purposes.
Although
we have identified some potential uses of the net proceeds to be received upon completion of this offering, we cannot specify these uses
with certainty. Our management will have broad discretion in the application of the net proceeds from this offering and could use them
for purposes other than those contemplated at the time of this offering. Our stockholders may not agree with the manner in which our
management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that
may not result in our being profitable or increase our market value.
Pending
application of the net proceeds for the purposes as described above, we may invest the net proceeds in short-term, interest-bearing securities,
investment grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. government.
DIVIDEND
POLICY
We
have never declared or paid cash dividends on our capital stock. We currently intend to retain our future earnings, if any, for use in
our business and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will
be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating
results, current and anticipated cash needs and plans for expansion.
PLAN
OF DISTRIBUTION
We
have entered into the Offering Agreement, dated as of June 1, 2022, as amended, with Wainwright as sales agent under which we
may issue and sell up to $6,300,000 of shares of our common stock from time to time through Wainwright as our agent. The Offering Agreement
provides that sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be “at-the-market”
equity offerings as defined in Rule 415(a)(4) promulgated under the Securities Act. If we and Wainwright agree on any method of distribution
other than sales of shares of our common stock into the Nasdaq Capital Market or another existing trading market in the United States
at market prices, we will file a further prospectus supplement providing all information about such offering as required by Rule 424(b)
under the Securities Act.
From
time to time during the term of the Offering Agreement, we may deliver a sales notice to the Sales Agent specifying the length of the
selling period, the amount of common stock to be sold and the minimum price below which sales may not be made. Upon receipt of a sales
notice from us, and subject to the terms and conditions of the Offering Agreement, the Sales Agent agrees to use its commercially reasonable
efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such shares of our common stock
on such terms. We or the Sales Agent may suspend the offering of our common stock at any time upon proper notice to the other, at which
time the sales notice will immediately terminate. Settlement for sales of our common stock will occur at 10:00 a.m. (New York City time),
or at some other time that is agreed upon by us and Wainwright in connection with a particular transaction, on the second trading day
following the date any sales were made, unless we otherwise agree with the Sales Agent. The obligation of the Sales Agent under the Offering
Agreement to sell shares of our common stock pursuant to any sales notice is subject to a number of conditions, which the Sales Agent
may waive in its sole discretion. Sales of our common stock as contemplated in this prospectus will be settled through the facilities
of The Depository Trust Company or by such other means as we and Wainwright may agree upon. There is no arrangement for funds to be received
in an escrow, trust or similar arrangement.
We
will pay the Sales Agent a placement fee of 3.0% of the gross sales price of the shares of our common stock that the Sales Agent sells
pursuant to the Offering Agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual
total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse
Wainwright for certain specified expenses, including the fees and disbursements of its legal counsel in an amount not to exceed $50,000.
Additionally, pursuant to the terms of the Offering Agreement, we agreed to reimburse Wainwright for the documented fees and costs
of its legal counsel reasonably incurred in connection with Wainwright’s ongoing diligence, drafting and other filing requirements
arising from the transactions contemplated by the Offering Agreement in an amount not to exceed $2,500 in the aggregate per calendar
quarter.
In
connection with the sale of the common stock on our behalf, Wainwright will be deemed to be an “underwriter” within the meaning
of the Securities Act and the compensation of Wainwright will be deemed to be underwriting commissions or discounts. We have agreed to
provide indemnification and contribution to Wainwright against certain civil liabilities, including liabilities under the Securities
Act.
We
will report at least quarterly the number of shares of our common stock sold through the Sales Agent, as our agent, in this offering
and, to the extent applicable, the number of shares of our common stock issued upon settlement of any terms agreements, and the net proceeds
to us in connection with such sales of our common stock.
The
offering of our common stock pursuant to the Offering Agreement will terminate upon the earliest of) the sale of all of our common stock
subject to the Offering Agreement or termination of the Offering Agreement as permitted therein.
To
the extent required by Regulation M, Wainwright will not engage in any market making activities involving our shares of common stock
while the offering is ongoing under this prospectus supplement.
Wainwright
and certain of its affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the
ordinary course of business with us or our affiliates. Wainwright previously acted as our placement agent in our private placement that
closed in August 2021. Wainwright and such affiliates have received, or may in the future receive, customary fees and expenses for these
transactions. In addition, in the ordinary course of its various business activities, Wainwright and its affiliates may make or hold
a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(which may include bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. Wainwright or its affiliates may also make investment recommendations
and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend
to clients that they acquire, long and/or short positions in such securities and instruments.
We
estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Wainwright under the terms of
the Offering Agreement, will be approximately $300,000.
Our
common stock is traded on the Nasdaq Capital Market under the symbol “INDP.”
LEGAL
MATTERS
The
validity of the shares of common stock offered hereby will be passed upon for us by McDermott Will & Emery LLP, New York, New York.
Haynes and Boone, LLP, New York, New York is counsel for Wainwright in connection with this offering
EXPERTS
Our
financial statements as of December 31,
2021 and 2020, and for each of the years then ended, have been incorporated by reference herein in reliance upon the report of Haskell
& White LLP, independent registered public accounting firm, and upon the authority of said firm as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus supplement constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the
SEC’s rules, this prospectus and any prospectus supplement, which form a part of the registration statement, do not contain all
the information that is included in the registration statement. You will find additional information about us in the registration statement.
Any statements made in this prospectus supplement concerning legal documents are not necessarily complete and you should read the documents
that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document
or matter.
We
are subject to the informational requirements of the Exchange Act, and, in accordance with those requirements, file annual, quarterly
and current reports, proxy statements and other information with the SEC. Such reports, proxy statements and other information, as well
as this registration statement and the exhibits and schedules thereto, are available on the SEC website at www.sec.gov. Copies of these
documents may also be accessed on our website at www.indaptusrx.com. Our internet website and the information contained therein or connected
thereto are not incorporated into this prospectus or any amendment or supplement thereto.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The SEC’s rules allow
us to “incorporate by reference” information into this prospectus supplement, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed
to be part of this prospectus supplement, and subsequent information that we file with the SEC will automatically update and supersede
that information. Any statement contained in this prospectus supplement or a previously filed document incorporated by reference will
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus supplement
or a subsequently filed document incorporated by reference modifies or replaces that statement.
This prospectus supplement
and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with
the SEC:
|
● |
our
Annual Report on Form 10-K for the fiscal year ended on December 31, 2021, filed with the
SEC on March 21, 2022;
|
|
|
|
|
● |
our
Quarterly Report on Form 10-Q for the quarter ended on March 31, 2022, filed with the SEC on May 12, 2022; |
|
|
|
|
● |
our Quarterly Report on Form 10-Q for the quarter ended on June 30, 2022, filed with the SEC on August 8, 2022; |
|
|
|
|
● |
our
Current Reports on Form 8-K (other than the information furnished pursuant to Item 2.02 or
7.01 thereof or related exhibits furnished pursuant to Item 9.01 thereof) filed with the
SEC on January 3, 2022, February 1, 2022, May 19, 2022, June 1, 2022 and July 21, 2022; and
|
|
|
|
|
● |
the
description of our shares of common stock contained in Item 1 of the Registration Statement on Form 8-A (File No. 001-40652), filed
with the SEC on July 23, 2021, including any amendment or report filed for the purpose of updating such description. |
All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act in this prospectus
supplement, prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial
registration statement of which this prospectus supplement is a part and prior to the effectiveness of the registration statement, but
excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and
deemed to be part of this prospectus from the date of the filing of such reports and documents.
We
will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this
prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. You may request
a copy of any or all of these filings, at no cost, by writing or telephoning us at: Nir Sassi, Chief Financial Officer, 3 Columbus Circle,
15th Floor, New York, NY 10019. You may also access the documents incorporated by reference in this prospectus through our website
at www.indaptus.com. Except for the specific incorporated documents listed above, no information available on or through our website
shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part.
PROSPECTUS
$200,000,000
Common
Stock
Preferred
Stock
Subscription
Rights
Debt
Securities
Warrants
Units
INDAPTUS
THERAPEUTICS, INC.
We
may offer, issue and sell from time to time up to $200,000,000, of our common stock, preferred stock, subscription rights, debt securities,
warrants and a combination of such securities, separately or as units, in one or more offerings. This prospectus provides a general description
of offerings of these securities that we may undertake.
We
refer to the shares of common stock, preferred stock, subscription rights, debt securities, warrants and units collectively as “securities”
in this prospectus.
Each
time we sell securities pursuant to this prospectus, we will provide in a supplement to this prospectus the price and any other material
terms of any such offering. Any prospectus supplement may also add, update or change information contained in this prospectus. You should
read this prospectus and any applicable prospectus supplement, as well as the documents incorporated by reference or deemed incorporated
by reference into this prospectus, carefully before you invest in any securities. This prospectus may not be used to offer or sell
securities unless accompanied by a prospectus supplement.
We
may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents
or dealers, on or off the Nasdaq Capital Market, at prevailing market prices or at privately negotiated prices. If any underwriters,
agents or dealers are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names
of the underwriter, agent or dealer and any applicable fees, commissions or discounts.
Our
shares of common stock are traded on the Nasdaq Capital Market under the symbol “INDP.” The last reported sale price of our
shares of common stock, as reported on the Nasdaq Capital Market on August 31, 2022 was $2.52.
The
aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was $19,171,306,
which was calculated based on 8,258,597 shares of common stock outstanding, as of August 31, 2022, of which 5,757,149 shares were
held by non-affiliates, and a price per share of $3.33 which was the closing sale price of our common stock on the Nasdaq Capital Market
on August 5, 2022. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months
prior to and including the date of this prospectus.
Investing
in our securities involves risks. See the section entitled “Risk Factors” included in or incorporated by reference into the
accompanying prospectus supplement beginning on page 2 and in the documents we incorporate by reference in this prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is September 9, 2022
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf”
registration process. Under this shelf registration process, we may offer and sell separately or together in any combination the securities
described in this prospectus in one or more offerings up to a total price to the public of $200,000,000. The offer and sale of securities
under this prospectus may be made from time to time, in one or more offerings, in any manner described under the section in this prospectus
entitled “Plan of Distribution.” This prospectus does not contain all of the information set forth in the registration statement,
certain parts of which are omitted in accordance with the rules and regulations of the SEC. Accordingly, you should refer to the registration
statement and its exhibits for further information about us and our securities. Copies of the registration statement and its exhibits
are on file with the SEC. Statements contained in this prospectus concerning the documents we have filed with the SEC are not intended
to be comprehensive, and in each instance we refer you to a copy of the actual document filed as an exhibit to the registration statement
or otherwise filed with the SEC.
This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities we will provide this
prospectus and a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement
may also add, update or change information contained in this prospectus, and may also contain information about any material federal
income tax considerations relating to the securities covered by the prospectus supplement. You should carefully read both this prospectus
and any prospectus supplement together with additional information under the headings “Where You Can Find More Information”
and “Incorporation of Certain Documents by Reference.”
The
prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities offered;
the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of the
securities.
We
have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus
or any accompanying prospectus supplement or any “free writing prospectus.” We are offering to sell, and seeking offers to
buy, securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus and in any accompanying
prospectus supplement is accurate only as of the dates of their covers, regardless of the time of delivery of this prospectus or any
prospectus supplement or of any sale of our securities. Our business, financial condition, results of operations, and prospects may have
changed since those dates. You should rely only on the information contained or incorporated by reference in this prospectus or any accompanying
prospectus supplement. To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement,
you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent
with a statement in another document having a later date — for example, a document incorporated by reference into this prospectus
or any prospectus supplement — the statement in the document having the later date modifies or supersedes the earlier statement.
This
prospectus incorporates by reference market data and certain industry data and forecasts that were obtained from market research databases,
consultant surveys commissioned by us, publicly available information, reports of governmental agencies and industry publications and
surveys. Industry surveys, publications, consultant surveys commissioned by us and forecasts generally state that the information contained
therein has been obtained from sources believed to be reliable. We have relied on certain data from third-party sources, including internal
surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of the industry.
Statements as to our market position are based on the most currently available data. While we are not aware of any misstatements regarding
the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based
on various factors, including those discussed or referred to under the heading “Risk Factors” in this prospectus, and under
similar headings in the other documents that are incorporated herein by reference.
Certain
figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables
may not be an arithmetic aggregation of the figures that precede them.
All
references to “we,” “us,” “our,” “Indaptus Therapeutics”, “Indaptus”, “the
Company” and “our company”, in this prospectus are to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.) and,
where appropriate, its consolidated subsidiaries Intec Pharma Ltd. and Decoy Biosystems, Inc. References to “Intec Parent”
refer to Intec Parent, Inc., the successor of Intec Pharma Ltd. following the Domestication Merger, references to “Intec Israel”
refer to Intec Pharma Ltd., the predecessor of Indaptus prior to the Domestication Merger, and references to “Decoy” refer
to Decoy Biosystems, Inc., the entity acquired by Indaptus in connection with the Merger described elsewhere in this prospectus.
RISK
FACTORS
An
investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities
will contain a discussion of the risks applicable to an investment in our securities. Before deciding whether to invest in our securities,
you should carefully consider the specific factors discussed under the heading “Risk Factors” in the applicable prospectus
supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing
or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item
1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and any subsequent Quarterly
Report on Form 10-Q or Current Report on Form 8-K which are incorporated herein by reference, as updated or superseded by the risks and
uncertainties described under similar headings in the other documents that are filed after the date hereof and incorporated by reference
into this prospectus and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are
not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
affect our operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should
not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects,
financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock to decline,
resulting in a loss of all or part of your investment. Please also read carefully the section below entitled “Forward-Looking Statements.”
FORWARD-LOOKING
STATEMENTS
This
prospectus, including the information incorporated by reference into this prospectus, contains, and any prospectus supplement may contain
statements that are forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product
development efforts, business, financial condition, results of operations, strategies, plans and prospects. In addition, from time to
time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can
be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,”
“may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,”
“will,” “project,” “forecast,” “continue” or their negatives or variations of these words
or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements
may be included in, among other things, various filings made by us with the SEC, press releases or oral statements made by or with the
approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially
from the activities and results anticipated in forward-looking statements, including, but not limited to:
|
● |
our
plans to develop and potentially commercialize our technology; |
|
|
|
|
● |
the
timing and cost of our planned investigational new drug application and any clinical trials; |
|
|
|
|
● |
the
completion and receipt of favorable results in any clinical trials; |
|
|
|
|
● |
our
ability to obtain and maintain regulatory approval of any product candidate; |
|
|
|
|
● |
our
ability to protect and maintain our intellectual property and licensing arrangements; |
|
|
|
|
● |
our
ability to develop, manufacture and commercialize our product candidates; |
|
|
|
|
● |
the
risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation;
and |
|
|
|
|
● |
our
estimates regarding future revenue, expenses capital requirements and the need for additional financing. |
|
|
|
We
believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known
and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance
or achievements to be materially different from those anticipated by the forward-looking statements. We discuss or refer you to
many of these risks in this prospectus in greater detail under the heading “Risk Factors” and elsewhere in this prospectus.
Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.
All
forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified
in their entirety by the cautionary statements included in this prospectus. We undertake no obligations to update or revise forward-looking
statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except
as required by law. In evaluating forward-looking statements, you should consider these risks and uncertainties and not place undue reliance
on our forward-looking statements.
PROSPECTUS
SUMMARY
Our
Business
We
are a pre-clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
Our technology has evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient
activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted
package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single
strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability
to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral
activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint
therapy, targeted antibody therapy and low-dose chemotherapy in pre-clinical models. Tumor eradication by our technology has demonstrated
activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen
in pre-clinical models. We have carried out successful GMP manufacturing of our lead clinical candidate, Decoy20, and completed other
IND-enabling studies.
Unlike
many competitor products, our technology does not depend on targeting with or to a specific antigen, providing broad applicability across
multiple indications. Our product candidates are designed to have a much shorter half-life and produce less systemic exposure than small
molecule, antibody or human cell-based therapies, potentially reducing the risk of non-specific auto-immune reactions. Our technology
produces single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal and pancreatic
tumors and has also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency
virus (HIV) infections in pre-clinical models. In May 2022, the U.S. Food and Drug Administration cleared our Investigational New Drug,
or IND, application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed
and plan to commence a Phase 1 clinical trial in the second half of 2022 targeting solid tumors. Target indications include, but not limited to, colorectal, hepatocellular (± HBV), bladder, cervical
and pancreatic carcinoma.
Decoy
Merger
On
August 3, 2021, we completed our merger with Decoy following the satisfaction or waiver of the conditions set forth in the Merger Agreement,
dated as of March 15, 2021 among the Company, Decoy, Intec Israel, Domestication Merger Sub Ltd., an Israeli company and a wholly-owned
subsidiary of the Company, or Domestication Merger Sub, and Dillon Merger Subsidiary Inc., a Delaware corporation and wholly owned subsidiary
of the Company, or Merger Sub, pursuant to which Merger Sub merged with and into Decoy, with Decoy surviving as a wholly owned subsidiary
of the Company, or the Merger, and the business conducted by Decoy became the business conducted by the combined company.
Previously,
on July 27, 2021, we, Intec Israel and Domestication Merger Sub completed the previously announced domestication merger pursuant to the
terms and conditions of the Domestication Merger Agreement, whereby Domestication Merger Sub merged with and into Intec Israel, with
Intec Israel being the surviving entity and a wholly-owned subsidiary of ours. At the time of the Domestication Merger, Intec Israel
continued to possess all of its assets, rights, powers and property as constituted immediately prior to the Domestication Merger and
continued to be subject to all of its debts, liabilities and obligations as constituted immediately prior to the Domestication Merger.
Also,
in connection with the Merger, we changed our name from “Intec Parent, Inc.” to “Indaptus Therapeutics, Inc.”.
Following
completion of the Merger, our shares of common stock commenced trading at market open on August 4, 2021, on the Nasdaq Capital Market
under the name “Indaptus Therapeutics, Inc.” and ticker symbol “INDP” and under the new CUSIP 45339J 105.
Winding
Down of Accordion Pill Business
In
connection with the completion of the Merger, on August 4, 2021, our board of directors determined to wind down the Accordion Pill business
of Intec Israel which was recently completed.
In
connection with the winding down, we laid off all our employees and we terminated our contracts with counterparties, including the termination
of the Process Development Agreement between Intec Israel and LTS Lohmann Therapie Systeme AG, and the termination of the unprotected
lease agreement between Intec Israel and its landlord for the lease of offices located in Jerusalem, Israel.
Private
Placement
In
connection with the Merger, on July 23, 2021, we entered into a securities purchase agreement, or the Purchase Agreement, with a certain
institutional investor, or the Purchaser, pursuant to which we agreed to sell and issue, in a private placement, or the Private Placement,
a pre-funded warrant to purchase up to 2,727,273 shares of our common stock, or the Pre-funded Warrant, and a warrant to purchase up
to 2,727,273 of our common stock at a purchase price of $10.99 per Pre-funded Warrant and associated Warrant, for aggregate gross proceeds
to us of approximately $30.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
The Warrant has a term of five and one-half years, is exercisable immediately following the issuance date and has an exercise price of
$11.00 per share, subject to adjustment as set forth therein.
On
August 3, 2021, the Private Placement closed and in September 2021, the Pre-Funded Warrants were fully exercised. In addition, we issued
to the placement agent a warrant to purchase 136,364 shares of our common stock at an exercise price of $13.75.
Corporate
Information
Our
principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019 and our telephone number is (646) 427-2727. Our website address is http://www.indaptusrx.com. The information contained on, or that can be accessed through, our website
is neither a part of nor incorporated into this prospectus. We have included our website address in this prospectus solely as an inactive
textual reference.
USE
OF PROCEEDS
Unless
otherwise indicated in an accompanying prospectus supplement, the net proceeds from the sale of securities will be used for our research
and development costs, including the conduct of one or more clinical trials and process development and manufacturing, working capital
and other general corporate purposes. Pending application of the net proceeds for the purposes as described above, we may invest the
net proceeds in short-term, interest-bearing securities, investment grade securities, certificates of deposit or direct or guaranteed
obligations of the U.S. government. When specific securities are offered, the prospectus supplement relating thereto will set forth our
intended use of the net proceeds that we receive from the sale of such securities.
THE
SECURITIES WE MAY OFFER
General
The
descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize all of the
material terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement
relating to any securities the particular terms of the securities offered by that prospectus supplement. If we indicate in the applicable
prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We may also include in the prospectus
supplement information about material United States federal income tax considerations relating to the securities, and the securities
exchange, if any, on which the securities will be listed.
We
may sell from time to time, in one or more offerings:
|
● |
common
stock; |
|
|
|
|
● |
preferred
stock; |
|
|
|
|
● |
subscription
rights; |
|
|
|
|
● |
debt
securities; |
|
|
|
|
● |
warrants; |
|
|
|
|
● |
units
consisting of any combination of the securities listed above. |
In
this prospectus, we refer to the common stock, preferred stock, subscription rights, debt securities, warrants and units collectively
as “securities.” The total dollar amount of all securities that we may sell will not exceed $200,000,000.
If
we issue debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar
amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original
principal amount of the debt securities.
This
prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.
DESCRIPTION
OF CAPITAL STOCK
General
The
following description of our capital stock is a summary. This summary is subject to the General Corporation Law of Delaware, or the DGCL,
and the complete text of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws.
Our
authorized capital stock consists of shares made up of 200,000,000 shares of common stock, par value $0.01 per share and 5,000,000 shares
of undesignated preferred stock, par value $0.01 per share.
Common
stock
Each
share of our common stock outstanding is entitled to one vote on all matters on which our stockholders generally are entitled to vote.
However, holders of our common stock are not entitled to vote on any amendment to the Amended and Restated Certificate of Incorporation
that relates solely to the terms of one or more outstanding classes or series of preferred stock if the holders of such affected classes
or series are entitled, either separately or together with the holders of one or more other such class or series, to vote thereon pursuant
to the Amended and Restated Certificate of Incorporation or the DGCL.
Generally,
the Amended and Restated Bylaws provide that, subject to applicable law or the Amended and Restated Certificate of Incorporation and/or
the Amended and Restated Bylaws, all corporate actions to be taken by vote of the stockholders are authorized by a majority of the votes
cast by the stockholders entitled to vote thereon who are present in person, or by remote communication, if applicable, or represented
by proxy, and where a separate vote by class or series is required, a majority of the votes cast by the stockholders of such class or
series who are present in person, or by remote communication, if applicable, or represented by proxy will be the act of such class or
series. Directors are elected by a plurality of the votes cast at a meeting of our stockholders for the election of directors at which
a quorum is present.
Subject
to the rights of holders of any then outstanding class or series of preferred stock, holders of our common stock are entitled to receive
dividends and other distributions in cash, stock or property as the board of directors may declare thereon from time to time, and share
equally on a per share basis in all such dividends and other distributions. In the event of our dissolution, whether voluntary or involuntary,
after the payment in full of the amounts required to be paid to the holders of any outstanding class or series of preferred stock, our
remaining assets and funds available for distribution will be distributed pro rata to the holders of our Common stock in proportion to
the number of shares held by them and to the holders of any class or series of preferred stock entitled to a distribution. Holders of
our Common stock do not have preemptive rights to purchase shares of our Common stock. All outstanding shares of our Common stock are
fully paid and non- assessable. The rights, preferences and privileges of holders of our Common stock are subject to those of the holders
of any outstanding class or series of our preferred stock that we may issue in the future.
Blank
Check Preferred Stock
Our
board of directors may, from time to time, authorize the issuance of one or more classes or series of preferred stock without stockholder
approval. The Amended and Restated Certificate of Incorporation permits us to issue up to 5,000,000 shares of preferred stock. The number
of authorized shares of preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by
the affirmative vote of the holders of a majority of our capital stock entitled to vote thereon, without a separate class vote of the
holders of preferred stock, or any separate series votes of any series thereof, unless a vote of any such holders is required pursuant
to the terms of any preferred stock certificate of designations.
Subject
to the provisions of the Amended and Restated Certificate of Incorporation and limitations prescribed by law, our board of directors
is expressly authorized, by resolution or resolutions, to provide, out of the unissued shares of preferred stock, for classes and series
of preferred stock. The board of directors may fix the number of shares constituting such class or series and the designation of such
class or series and the powers (including voting, if any), preferences and relative, participating, optional or other special rights,
if any, and any qualifications, limitations or restrictions thereof, of the shares of such class or series. Each class or series is appropriately
designated by a distinguishing designation prior to the issuance of any shares thereof. The powers (including voting, if any), preferences
and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations
or restrictions thereof, if any, may differ from those of any and all other classes and series of preferred stock at any time outstanding.
The
issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, may adversely
affect the rights our common stockholders by, among other things:
|
● |
restricting
dividends on the common stock; |
|
|
|
|
● |
diluting
the voting power of the common stock; |
|
|
|
|
● |
impairing
the liquidation rights of the common stock; or |
|
|
|
|
● |
delaying
or preventing a change in control without further action by the stockholders. |
As
a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock.
There is no current intention for us to issue any shares of preferred stock.
Anti-takeover
Effects of Certain Provisions of the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws
General
The
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws contains provisions that are intended to enhance the
likelihood of continuity and stability in the composition of our board of directors and that could make it more difficult to acquire
control of us by means of a tender offer, open market purchases, a proxy contest or otherwise. A description of these provisions is set
forth below.
Delaware
Anti-Takeover Law
We
are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from
engaging in a “business combination” with an “interested stockholder” for a period of three years after the date
of the transaction in which the person became an interested stockholder, unless:
|
● |
prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder; |
|
|
|
|
● |
upon
consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding specified shares;
or |
|
|
|
|
● |
at
or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an
annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the
outstanding voting stock which is not owned by the interested stockholder. |
Section
203 defines a “business combination” to include:
|
● |
any
merger or consolidation involving the corporation and the interested stockholder; |
|
|
|
|
● |
any
sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation to or with
the interested stockholder; |
|
|
|
|
● |
subject
to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the
interested stockholder; |
|
|
|
|
● |
subject
to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of
any class or series of the corporation beneficially owned by the interested stockholder; or |
|
|
|
|
● |
the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation. |
In
general, Section 203 defines an “interested stockholder” as any person that is:
|
● |
the
owner of 15% or more of the outstanding voting stock of the corporation; |
|
● |
an
affiliate or associate of the corporation who was the owner of 15% or more of the outstanding voting stock of the corporation at
any time within three years immediately prior to the relevant date; or |
|
|
|
|
● |
the
affiliates and associates of the above. |
Under
specific circumstances, Section 203 makes it more difficult for an “interested stockholder” to effect various business combinations
with a corporation for a three-year period, although the stockholders may, by adopting an amendment to the corporation’s certificate
of incorporation or bylaws, elect not to be governed by Section 203. The election not to be governed by Section 203 is effective (i)
upon the filing of the certificate of amendment with the Secretary of State of the State of Delaware or the adoption of the amendment
to the bylaws, as applicable, for a corporation that does not have a class of voting stock listed on a national securities exchange or
held of record by more than 2,000 stockholders or (ii) 12 months after such action for all other corporations.
Our
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws do not exclude us from the restrictions of Section
203. We anticipate that the provisions of Section 203 might encourage companies interested in acquiring us to negotiate in advance
with its board of directors since the stockholder approval requirement would be avoided if a majority of the directors then in office
approve either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder.
No
Cumulative Voting
Under
Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. The Amended and Restated Certificate of Incorporation does not grant stockholders the right to vote cumulatively.
Blank
Check Preferred Stock
We
believe that the availability of the preferred stock under the Amended and Restated Certificate of Incorporation provides us with flexibility
in addressing corporate issues that may arise. Having these authorized shares available for issuance allows us to issue shares of preferred
stock without the expense and delay of a special stockholders’ meeting. The authorized shares of preferred stock, as well as shares
of common stock, is available for issuance without further action by our stockholders, with the exception of any actions required by
applicable law or the rules of any stock exchange on which our securities may be listed. The board of directors has the power, subject
to applicable law, to issue classes or series of preferred stock that could, depending on the terms of the class or series, impede the
completion of a merger, tender offer or other takeover attempt.
Advance
Notice Procedure
The
Amended and Restated Bylaws provide an advance notice procedure for stockholders to nominate director candidates for election or to bring
business before an annual meeting of stockholders, including proposed nominations of persons for election to the board of directors.
The
Amended and Restated Bylaws provide that as to the notice of stockholder proposals of business to be brought at the annual meeting of
stockholders, notice must be delivered to our secretary (i) not less than 90 days nor more than 120 days prior to the first anniversary
of the preceding year’s annual meeting or (ii) (x) if the date of the annual meeting is advanced by more than 30 days or delayed
by more than 60 days from the first anniversary of the preceding year’s annual meeting, or (y) with respect to the first annual
meeting held after the issuance of securities pursuant to the registration statement of which this prospectus forms a part, not more
than 120 days nor less than 90 days prior to the date of such annual meeting or, if later, the 10th day following the day on which public
announcement of the date of such meeting is first made by us. In addition, any proposed business other than the nomination of persons
for election to our board of directors must constitute a proper matter for stockholder action.
The
Amended and Restated Bylaws provide that in the case of nominations for election at an annual meeting, notice must be delivered to, or
mailed and received at, our principal executive offices (i) not less than 90 days nor more than 120 days prior to the first anniversary
of the preceding year’s annual meeting or (ii) (x) if the date of the annual meeting is advanced by more than 30 days or delayed
by more than 60 days from the first anniversary of the preceding year’s annual meeting, or (y) with respect to the first annual
meeting held after the issuance of securities pursuant to the registration statement of which this prospectus forms a part, not more
than 120 days nor less than 90 days prior to the date of such annual meeting or, if later, the 10th day following the day on which public
announcement of the date of such annual meeting is first made by us. In the case of nominations for election at a special meeting of
stockholders called for the election of directors, notice must be delivered to, or mailed and received at, our principal executive offices
(i) not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting or (ii)
if later, the 10th day following the day on which public announcement of the date of such special meeting is first made by us. In addition,
each such stockholder’s notice must include certain information regarding the stockholder and the director nominee as set forth
in the Amended and Restated Bylaws as described under the section entitled “Differences in Shareholder Rights.”
Staggered
Board
Our
Amended and Restated Certificate of Incorporation provides that our board of directors is be divided into three classes of directors,
with the classes as nearly equal in number as possible. At each annual meeting of the stockholders, a class of directors will be elected
for a three-year term to succeed the directors of the same class whose terms are then expiring. As a result approximately one-third of
our directors is elected each year. The initial term of office of the directors of Class I shall expire as of our first annual meeting
of stockholders; the initial term of office of the directors of Class II shall expire as of our second annual meeting; and the initial
term of office of the directors of Class III shall expire as of the third annual meeting of our stockholders.
|
● |
The
Class I directors are Hila Karah and Dr. Mark J. Gilbert; |
|
|
|
|
● |
The
Class II directors are Anthony Maddaluna, Brian O’Callaghan and William B. Hayes; and |
|
|
|
|
● |
The
Class III directors are Jeffrey A. Meckler, Michael J. Newman, Ph.D. and Dr. Roger J. Pomerantz. |
Our
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the number of directors shall be fixed
from time to time by a resolution of the majority of its board of directors. Any additional directorships resulting from an increase
in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist of one-third
of the board of directors.
The
division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect
a change of its management or a change in control.
Action
by Written Consent; Special Meetings of Stockholders
Our
Amended and Restated Certificate of Incorporation provide that stockholder action can be taken only at an annual or special meeting of
stockholders and cannot be taken by written consent in lieu of a meeting. Our Amended and Restated Certificate of Incorporation and Amended
and Restated Bylaws provides that, except as otherwise required by law, special meetings of the stockholders can be called only by the
board of directors, the chairperson of the board of directors, our chief executive officer or our president (in the absence of a chief
executive officer). Except as provided above, our stockholders are not to be permitted to call a special meeting or to require the board
of directors to call a special meeting.
Removal
of Directors
Our
Amended and Restated Certificate of Incorporation does not provide for the removal of directors by stockholders.
Exclusive
Forum
Our
Amended and Restated Certificate of Incorporation provide that unless we consent in writing to the selection of an alternative forum,
the Court of Chancery of the State of Delaware shall be, to the fullest extent permitted by law, the sole and exclusive forum for any
derivative action or proceeding brought on its behalf, any action asserting a claim for breach of a fiduciary duty owed by any of its
directors and officers to it or its stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, its Amended
and Restated Certificate of Incorporation, its Amended and Restated Bylaws, or any action asserting a claim governed by the internal
affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities
Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims
may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to
enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.
These
choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or its directors, officers or other team members, which may discourage such lawsuits against us and our directors, officers and
other team members.
Federal
Forum for Securities Act Claims
Section
22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder. However, our Amended and Restated Certificate of Incorporation
contains a federal forum provision which provides that unless we consent in writing to the selection of an alternative forum, the federal
district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital
stock are deemed to have notice of and consented to this provision. The Supreme Court of Delaware has held that this type of exclusive
federal forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce
such a provision, if applicable.
This
choice of federal forum for Securities Act claims may limit a stockholder’s ability to bring a claim in a judicial forum that it
finds favorable, which may discourage such lawsuits against us and our directors, officers and other team members.
Stock
Exchange Listing
Our
common stock is traded on the Nasdaq Capital Market under the trading symbol “INDP.”
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is VStock Transfer, LLC, 18 Lafayette Pl, Woodmere, NY 11598.
DESCRIPTION
OF SUBSCRIPTION RIGHTS
We
may issue subscription rights to purchase our shares of common stock, preferred stock or debt securities. These subscription rights may
be issued independently or together with any other security offered hereby and may or may not be transferable by the shareholder receiving
the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a standby arrangement
with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase
any securities remaining unsubscribed for after such offering.
The
prospectus supplement relating to any subscription rights we offer will, to the extent applicable, include specific terms relating to
the offering, including some or all of the following:
|
● |
the
price, if any, for the subscription rights; |
|
|
|
|
● |
the
exercise price payable for each share upon the exercise of the subscription rights; |
|
|
|
|
● |
the
number of subscription rights to be issued to each shareholder; |
|
|
|
|
● |
the
number and terms of the shares which may be purchased per each subscription right; |
|
|
|
|
● |
the
extent to which the subscription rights are transferable; |
|
|
|
|
● |
any
other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of
the subscription rights; |
|
|
|
|
● |
the
date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire; |
|
|
|
|
● |
the
extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities; and |
|
|
|
|
● |
if
applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into by us in connection
with the offering of subscription rights. |
The
description in the applicable prospectus supplement of any subscription rights we offer will not necessarily be complete and will be
qualified in its entirety by reference to the applicable subscription rights agreement, which will be filed with the SEC if we offer
subscription rights. For more information on how you can obtain copies of the applicable subscription rights agreement if we offer subscription
rights, see “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference” beginning
on page 33. We urge you to read the applicable subscription rights agreement and any applicable prospectus supplement in their entirety.
DESCRIPTION
OF DEBT SECURITIES
General
We
may issue senior and subordinated debt securities under indentures by and among us, certain of our subsidiaries, if any, and a trustee
to be named in the senior indenture, as the indenture trustee. Each indenture will be subject to, and governed by, the Trust Indenture
Act of 1939, as amended, or the Trust Indenture Act, and we may supplement the indenture from time to time.
This
prospectus summarizes the material provisions of the indentures and the debt securities that we may issue under the indentures. This
summary is not complete and may not describe all of the provisions of the indentures or of any of the debt securities that might be important
to you. For additional information, you should carefully read the forms of indenture and debt securities that are filed as exhibits to
the registration statement of which this prospectus forms a part and any definitive indentures, supplemental indentures and forms of
debt securities that are incorporated by reference as exhibits to such registration statement.
When
we offer to sell a particular series of debt securities, we will describe the specific terms of those debt securities in a supplement
to this prospectus. We will also indicate in the supplement whether the general terms in this prospectus apply to a particular series
of debt securities. Accordingly, for a description of the terms of a particular issue of debt securities, you should carefully read both
this prospectus and the applicable supplement.
In
the summary below, we have included references to the section numbers of the indentures so that you can easily locate the related provisions
in the indentures for additional detail. You should also refer to the applicable indenture for the definitions of any capitalized terms
that we use below but do not define in this prospectus. When we refer to particular sections of the indentures or to defined terms in
the indentures, we intend to incorporate by reference those sections and defined terms into this prospectus.
Terms
The
debt securities will be our direct obligations. The amount of debt securities we may offer under this prospectus is unlimited as to principal
amount. We may issue the debt securities, from time to time and in one or more series, established in or pursuant to authority granted
by one or more resolutions of our board of directors, and set forth in, or determined in the manner provided in, an officers’ certificate,
or established in one or more supplemental indentures. We may issue debt securities with terms different from those of our previously
issued debt securities.
Each
indenture provides that there may be more than one trustee under such indenture, each such trustee with respect to one or more series
of debt securities. Any trustee under the indentures may resign or be removed with respect to one or more series of debt securities,
and a successor trustee may be appointed to act with respect to that series. If two or more persons act as trustee
with respect to different series of debt securities, each trustee shall be a trustee of a trust under that indenture separate and apart
from the trust administered by any other trustee. Except as otherwise indicated in this prospectus, each trustee
may take any action described in this prospectus only with respect to the one or more series of debt securities for which it is trustee
under the relevant indenture.
You
should refer to the applicable supplement to this prospectus relating to a particular series of debt securities for the specific terms
of the debt securities, including, but not limited to:
|
● |
the
title of the debt securities, whether the debt securities will be guaranteed and the identity of the guarantor or guarantors, if
any; |
|
|
|
|
● |
the
total principal amount of the debt securities and any limit on the total principal amount; |
|
|
|
|
● |
the
price, expressed as a percentage of the principal amount of the debt securities, at which we will issue the debt securities and any
portion of the principal amount payable upon acceleration of the debt securities; |
|
|
|
|
● |
the
terms, if any, by which holders of the debt securities may convert or exchange the debt securities for our shares of common stock,
or any of our other securities or property; |
|
|
|
|
● |
if
the debt securities are convertible or exchangeable, any limitations on the ownership or transferability of the securities or property
into which holders may convert or exchange the debt securities; |
|
● |
the
date or dates, or the method for determining the date or dates, on which we will be obligated to pay the principal of the debt securities
and the amount of principal we will be obligated to pay; |
|
|
|
|
● |
the
rate or rates, which may be fixed or variable, at which the debt securities of the series will bear interest, if any, or the method
by which the rate or rates will be determined; |
|
|
|
|
● |
whether
the debt securities rank as senior, senior subordinated or subordinated or any combination thereof and the terms of any subordination; |
|
|
|
|
● |
the
date or dates, or the method for determining the date or dates, from which any interest will accrue on the debt securities, the dates
on which we will be obligated to pay any interest, the regular record dates, if any, for the interest payments, or the method by
which the dates will be determined, the persons to whom we will be obligated to pay interest and the basis upon which interest will
be calculated, if other than that of a 360-day year consisting of twelve 30-day months; |
|
|
|
|
● |
the
place or places where the principal of, and any premium, make-whole amount, interest or additional amounts on, the debt securities
will be payable, where the holders of the debt securities may surrender their debt securities for conversion, transfer or exchange,
and where the holders may serve notices or demands to us in respect of the debt securities and the indenture]; |
|
|
|
|
● |
whether
the debt securities will be in registered or bearer form, and the terms and conditions relating to the form, and, if in registered
form, the denominations in which we will issue the debt securities if other than $1,000 or a multiple of $1,000 and, if in bearer
form, the denominations in which we will issue the debt securities if other than $5,000; |
|
|
|
|
● |
the
identity of the trustee of the debt securities of the series and, if other than the trustee, the identity of each security registrar
and/or paying agent for debt securities of the series; |
|
|
|
|
● |
the
period or periods during which the price or prices, including any premium at which, the currency or currencies in which, and the
other terms and conditions upon which, we may redeem the debt securities at our option, if we have such an option; |
|
|
|
|
● |
any
obligation that we have to redeem, repay or purchase debt securities under any sinking fund or similar provision or at the option
of a holder of debt securities and the terms and conditions upon which we will redeem, repay or purchase all or a portion of the
debt securities under that obligation; |
|
|
|
|
● |
the
currency or currencies in which we will sell the debt securities and in which the debt securities will be denominated and payable; |
|
|
|
|
● |
whether
the amount of payment of principal of, and any premium, make-whole amount or interest on, the debt securities of the series may be
determined with reference to an index, formula or other method and the manner in which the amounts will be determined; |
|
|
|
|
● |
whether
the principal of, and any premium, make-whole amount, additional amounts or interest on, the debt securities of the series are to
be payable, at our election or at the election of a holder of the debt securities, in a currency or currencies other than that in
which the debt securities are denominated or stated to be payable, the period or periods during which, and the terms and conditions
upon which, this election may be made, and the time and manner of, and identity of the exchange rate agent responsible for, determining
the exchange rate between the currency or currencies in which the debt securities are denominated or stated to be payable and the
currency or currencies in which the debt securities will be payable; |
|
|
|
|
● |
the
designation of the initial exchange rate agent, if any, or any depositaries; |
|
|
|
|
● |
any
provisions granting special rights to the holders of the debt securities of the series at the occurrence of named events; |
|
|
|
|
● |
any
additions to, modifications of or deletions from the terms of the debt securities with respect to the events of default or covenants
contained in the indenture; |
|
● |
whether
the debt securities of the series will be issued in certificated or book-entry form and the related terms and conditions, including
whether any debt securities will be issued in temporary and/or permanent global form, and if so, whether the owners of interests
in any permanent global debt security may exchange those interests for debt securities of that series and of like tenor of any authorized
form and denomination and the circumstances under which any exchanges may occur, if other than in the manner provided in the indenture, and, if debt securities of or within the series are to be issuable as a global debt security, the identity of the
depositary for such series; |
|
|
|
|
● |
the
date as of which any bearer securities, and/or temporary global debt security representing outstanding securities of or within the
series will be dated if other than the date of original issuance of the first debt security of the series to be issued; |
|
|
|
|
● |
if
the debt securities will be issued in definitive form only upon our receipt, or the trustee’s receipt, of certificates or other
documents, or upon the satisfaction of conditions, a description of those certificates, documents or conditions; |
|
|
|
|
● |
if
the debt securities will be issued upon the exercise of debt warrants, the time, manner and place for the debt securities to be authenticated
and delivered; |
|
|
|
|
● |
the
applicability, if any, of the defeasance and covenant defeasance provisions of the indenture, as described below under “Modification
of the Indentures—Discharge, Defeasance and Covenant Defeasance”; |
|
|
|
|
● |
any
applicable U.S. federal income tax consequences, including whether and under what circumstances we will pay any additional amounts,
as contemplated in the indenture on the debt securities, to any holder who is not a U.S. person in respect of any tax, assessment
or governmental charge withheld or deducted and, if we will pay additional amounts, whether, and on what terms, we will have the
option to redeem the debt securities in lieu of paying the additional amounts; |
|
|
|
|
● |
the
provisions, if any, relating to any security provided for the debt securities of the series; |
|
|
|
|
● |
any
other covenant or warranty included for the benefit of the debt securities of the series; |
|
|
|
|
● |
any
proposed listing of the debt securities on any securities exchange or market; and |
|
|
|
|
● |
any
other terms of the debt securities or of any guarantees issued in connection with the debt securities not inconsistent with the provisions
of the indenture. |
The
debt securities may provide for our payment of less than their entire principal amount if their maturity is accelerated as a result of
the occurrence and continuation of an event of default. If this is the case, the debt securities would have what is referred
to as “original issue discount.” Any special U.S. federal income tax, accounting and other considerations applicable to original
issue discount securities will be described in the applicable prospectus supplement.
We
may issue debt securities from time to time, with the principal amount payable on any principal payment date, or the amount of interest
payable on any interest payment date, to be determined by reference to one or more currencies or currency exchange rates, commodity prices,
equity indices or other factors. Holders of debt securities with these features may receive payment of a principal amount on any principal
payment date, or a payment of interest on any interest payment date, that is greater than or less than the amount of principal or interest
otherwise payable on the applicable dates, depending upon the value on those dates of the applicable currencies or currency exchange
rates, commodity prices, equity indices or other factors.
Information
as to the methods for determining the amount of principal or interest payable on any date, the currencies or currency exchange rates,
commodity prices, equity indices or other factors to which the amount payable on that date is linked and additional tax considerations
will be included in the applicable prospectus supplement. All debt securities of any one series will be substantially identical, except
as to denomination and except as may otherwise be provided by an officers’ certificate or in any supplement to the applicable indenture.
We are not required to issue all of the debt securities of a series at the same time, and, unless otherwise provided in the applicable
indenture, supplemental indenture or officers’ certificate, we may re-open a series without the consent of the holders of the debt
securities of that series to issue additional debt securities of that series.
The
indentures do not contain any provisions that limit our ability to incur indebtedness or that would protect holders of debt securities
in the event we become a party to a highly-leveraged or similar transaction in which we would incur or acquire a large amount of additional
debt, but such provisions may appear in the applicable prospectus supplement. You should refer to the applicable prospectus supplement
for information regarding any deletions from, modifications of or additions to the events of default or covenants that are described
below, including any addition of a covenant or other provision providing event risk or similar protection.
Guarantees
Debt
securities may be issued and unconditionally and irrevocably guaranteed by us or certain of our subsidiaries, if any, that are listed
as guarantors in the applicable supplement to this prospectus. Any guarantee would cover the timely payment of the principal of, and
any premium, make-whole amount, interest or sinking fund payments on, the debt securities, whether we make the payment at a maturity
date, as a result of acceleration or redemption or otherwise. We will more fully describe the existence and terms of any guarantee of
any of our debt securities by us or our subsidiaries in the prospectus supplement relating to those debt securities.
Denominations,
Interest, Registration and Transfer
Unless
the applicable prospectus supplement states otherwise, any debt securities of any series that we issue in registered form will be issued
in denominations of $1,000 and multiples of $1,000, and debt securities of any series that we issue in bearer form will be issued in
denominations of $5,000.
Unless
the applicable prospectus supplement states otherwise, the principal of, and any premium, make-whole amount or interest on, any series
of debt securities will be payable in the currency designated in the prospectus supplement at the corporate trust office of the trustee,
initially, the corporate trust office of the trustee to be named in the senior indenture. At our option, however, payment of interest
may be made by check mailed to the address of the person entitled to the interest payment as it appears in the security register for
the series or by wire transfer of funds to that person at an account maintained within the United States. We may at any time designate
additional paying agents or rescind designation of any paying agents or approve a change in the office through which any paying agent
acts, except that we will be required to maintain a paying agent in each place of payment for any series. All monies that we pay to a
paying agent for the payment of any principal of, or any premium, make-whole amount, interest or additional amounts on, any debt security
which remains unclaimed at the end of two years after that payment became due and payable will be repaid to us. After that time, the
holder of the debt security will be able to look only to us for payment.
Any
interest that we do not punctually pay on any interest payment date with respect to a debt security will cease to be payable to the holder
on the applicable regular record date and may either:
|
● |
be
paid to the holder at the close of business on a Special Record Date for the payment of defaulted interest, to be determined by the
trustee; or |
|
|
|
|
● |
be
paid at any time in any other lawful manner, as more fully described in the indentures. |
Subject
to certain limitations imposed upon debt securities issued in book-entry form, debt securities of any series will be exchangeable for
other debt securities of the same series and of the same total principal amount and authorized denomination upon the surrender of the
debt securities at the corporate trust office of the trustee. In addition, subject to certain limitations imposed upon debt securities
issued in book-entry form, the debt securities of any series may be surrendered for conversion, transfer or exchange at the corporate
trust office of the trustee. Every debt security surrendered for conversion, transfer or exchange must be duly endorsed or accompanied
by a written instrument of transfer. There will be no service charge for any transfer or exchange of any debt securities, but we may
require holders to pay any tax or other governmental charge payable in connection with the transfer or exchange.
If
the applicable prospectus supplement refers to us designating any transfer agent for any series of debt securities, in addition to the
trustee, we may at any time remove the transfer agent or approve a change in the location at which the transfer agent acts, except that
we will be required to maintain a transfer agent in each place of payment for any series of debt securities. We may at any time designate
additional transfer agents with respect to any series of debt securities.
Neither
we nor any trustee will be required to do any of the following:
|
● |
issue,
register the transfer of or exchange debt securities of any series during a period beginning at the opening of 15 business days before
there is a selection of debt securities of that series to be redeemed and ending at the close of business on the day of mailing or
publication of the relevant notice of redemption; |
|
● |
register
the transfer of or exchange any debt security, or portion thereof, called for redemption, except the unredeemed portion of any debt
security being only partially redeemed; |
|
|
|
|
● |
exchange
any debt security in bearer form that is selected for redemption, except that a debt security in bearer form may be exchanged for
a debt security in registered form of that series and like denomination, provided that the debt security in registered form must
be simultaneously surrendered for redemption; or |
|
|
|
|
● |
issue
or register the transfer or exchange of any debt security that has been surrendered for repayment at the option of the holder, except
the portion, if any, of the debt security that will not be partially or entirely repaid. |
Global
Debt Securities
The
debt securities of a series may be issued in the form of one or more fully registered global securities that will be deposited with a
depositary or with a custodian for a depositary identified in the prospectus supplement relating to the series and registered in the
name of the depositary or its nominee. In this case, we will issue one or more global securities in a denomination or total denominations
equal to the portion of the total principal amount of outstanding registered debt securities of the series to be represented by the global
security or securities. We expect that any global securities issued in the United States would be deposited with The Depositary Trust
Company, as depositary or its custodian. We may issue any global securities in fully registered form on a temporary or permanent basis.
Unless and until a global security is exchanged for debt securities in definitive registered form, a permanent global security may not
be transferred except as a whole by the depositary to its nominee or by a nominee to the depositary or another nominee, or by the depositary
or its nominee to a successor of the depositary or the successor depositary’s nominee.
The
specific terms of the depositary arrangement with respect to any series of debt securities to be represented by a registered global security
will be described in the applicable prospectus supplement. We anticipate that the following provisions will apply to depositary arrangements.
Ownership
of beneficial interests in a global security will be limited to persons that have accounts with, or are participants of, the depositary
for the registered global security, or persons that may hold interests through participants. When we issue a registered global security,
the depositary will credit, on its book-entry registration and transfer system, the participants’ accounts with the respective
principal amounts of the debt securities represented by the global security owned by those participants. The accounts to be credited
will be designated by any dealers, underwriters or agents participating in an offering of the debt securities, or by us or the trustee
if we are directly offering the debt securities. The participants’ ownership, and any transfer, of a registered global security
will be shown on records maintained by the depositary, and ownership of persons who hold debt securities through participants will be
reflected on the records of the participants. State and federal laws may impair a person’s ability to own, transfer or pledge interests
in a registered global security.
So
long as the depositary or its nominee is the registered owner of the global security, the depositary or its nominee, as the case may
be, will be considered the sole owner or holder of the debt securities represented by the global security for all purposes under the
applicable indenture. Except as set forth below, owners of beneficial interests in a global security will not be entitled to have the
debt securities represented by the registered global security registered in their names, will not receive or be entitled to receive physical
delivery of the debt securities in definitive form and will not be considered the owners or holders of the debt securities under the
applicable indenture. Accordingly, each person owning a beneficial interest in a registered global security must rely on the depositary’s
procedures and, if that person is not a participant, on the procedures of the participant through which that person owns its interest
to exercise any rights of a holder under the applicable indenture. We understand that under existing industry practices, if we request
any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action which
a holder is entitled to give or take under the applicable indenture, the depositary would authorize the participants holding the relevant
beneficial interests to give or take the action, and the participants would authorize beneficial owners owning through those participants
to give or take the action or would otherwise act upon the instructions of beneficial owners holding through them.
Payments
of principal of, and any premium, make-whole amount, interest or additional amounts on a registered global security will be made to the
depositary or its nominee, as the case may be, as the registered owner of the global security. Neither we, the trustee, the paying agent
nor the registrar, nor any other agent of ours or of the trustee, will have any responsibility or liability for any aspect of the records
relating to, or payments made on account of, beneficial ownership interests in the global security or for maintaining, supervising or
reviewing any records relating to the beneficial ownership interests.
We
expect that once the depositary receives any payment of principal of, any premium, make-whole amount, interest or additional amount on,
a registered global security, the depositary will immediately credit the participants’ accounts with payments in amounts proportionate
to their respective beneficial interests in the global security, as shown on the records of the depositary. We also expect that payments
by the participants to owners of beneficial interests in the registered global security held through the participants will be governed
by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers
in bearer form or registered in “street name,” and will be the responsibility of the participants.
If
the depositary is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, and we do not appoint a successor depositary within 90 days, we will issue debt securities
in definitive form in exchange for the registered global security. In addition, we may at any time and in our sole discretion decide
not to have any of the debt securities of a series represented by one or more global securities, and, in such event, we will issue debt
securities in definitive form in exchange for all of the global security or securities representing the debt securities. We will register
any debt securities issued in definitive form in exchange for a global security in the name or names that the depositary provides to
the trustee. We expect that those names will be based upon directions received by the depositary from the participants with respect to
ownership of beneficial interests in the global security.
Debt
securities in bearer form may also be issued in the form of one or more global securities that will be deposited with a common depositary
for Euroclear and Clearstream, or with a nominee for the depositary identified in the applicable prospectus supplement. We will describe
in the applicable prospectus supplement the specific terms and procedures of the depositary arrangement, including the specific terms
of the depositary arrangement and any specific procedures, for the issuance of debt securities in definitive form in exchange for a global
security in bearer form, with respect to any portion of a series of debt securities to be represented by a global security in bearer
form.
Merger,
Consolidation or Sale
We
may consolidate with, or sell, lease or convey all or substantially all of our assets to, or merge with or into, any other corporation,
trust or entity provided that:
|
● |
we
are the survivor in the transaction, or the survivor, if not us, is an entity organized under the laws of the United States or a
state of the United States, or the State of Israel, which entity expressly assumes by supplemental indenture the due and punctual
payment of the principal of, and any premium, make-whole amount, interest and additional amounts on, all of the outstanding debt
securities and the due and punctual performance and observance of all of the covenants and conditions contained in the indenture; |
|
|
|
|
● |
immediately
after giving effect to the transaction and treating any indebtedness that becomes an obligation of ours or one of our subsidiaries
as a result of the transaction as having been incurred by us or our subsidiary at the time of the transaction, there is no event
of default under the applicable indenture and no event which, after notice or the lapse of time, or both, would become an event of
default; and |
|
|
|
|
● |
we
deliver an officers’ certificate and an opinion of our legal counsel, each as to the satisfaction of conditions contained in
the applicable indenture. |
This
covenant would not apply to any recapitalization transaction, a change of control of us or a transaction in which we incur a large amount
of additional debt, unless the transactions or change of control included a merger, consolidation or transfer or lease of substantially
all of our assets. Except as may be described in the applicable prospectus supplement, there are no covenants or other provisions in
the indentures providing for a “put” right or increased interest or that would otherwise afford holders of debt securities
additional protection in the event of a recapitalization transaction, a change of control of us or a transaction in which we incur a
large amount of additional debt.
Certain
Covenants
Provision
of Financial Information
Whether
or not we are subject to Section 13 or 15(d) of the Exchange Act, we will file annual reports and other documents with the SEC pursuant
to Sections 13 and 15(d) of the Exchange Act as if we were so subject, on or prior to the dates by which we are or would have been required
to file those documents if we were so subject. In any event, we will:
|
● |
file
with the applicable trustee copies of the annual reports and other documents that we are or would be required to file with the SEC
under Sections 13 and 15(d) of the Exchange Act within 15 days of each of the respective dates by which we are or would have been
required to file those reports with the SEC; and |
|
|
|
|
● |
promptly
upon written request and payment of the reasonable cost of duplication and delivery, supply copies of those documents to holders
and any prospective holders of debt securities if filing those documents with the SEC is not permitted under the Exchange Act. |
Additional
Covenants
Any
additional covenants with respect to any series of debt securities will be described in the applicable prospectus supplement.
Events
of Default, Notice and Waiver
Except
as otherwise provided in the applicable prospectus supplement, the following events are “events of default” with respect
to any series of debt securities that we may issue under the indentures:
|
● |
we
fail for 30 days to pay any installment of interest or any additional amounts payable on any debt security of that series; |
|
|
|
|
● |
we
fail to pay the principal of, or any premium or make-whole amount on, any debt security of that series when due, either at maturity,
redemption or otherwise; |
|
|
|
|
● |
we
fail to make any sinking fund payment as required for any debt security of that series; |
|
|
|
|
● |
we
breach or fail to perform any covenant or warranty contained in the applicable indenture, other than a covenant added solely for
the benefit of a different series of debt securities issued under the applicable indenture or except as otherwise provided for in
the applicable indenture, and our breach or failure to perform continues for 60 days after we have received written notice in accordance
with the applicable indenture of our breach or failure to perform; |
|
|
|
|
● |
we
default under a bond, debenture, note, mortgage, indenture or instrument evidencing indebtedness for money borrowed by us, or by
any subsidiaries of ours that we have guaranteed or for which we are directly responsible or liable as obligor or guarantor, that
has a principal amount outstanding of $20,000,000 or more, other than indebtedness which is non-recourse to us or our subsidiaries,
which default has caused the indebtedness to become due and payable earlier than it would otherwise have become due and payable,
and the indebtedness has not been discharged or the acceleration has not been rescinded or annulled, within 30 days after written
notice was provided to us in accordance with the applicable indenture; |
|
|
|
|
● |
the
bankruptcy, insolvency or reorganization or court appointment of a receiver, liquidator or appointment of a trustee for us or of
any of our Significant Subsidiaries, or for all or substantially all of our properties or the properties of our Significant Subsidiaries; and |
|
|
|
|
● |
any
other event of default described in the applicable prospectus supplement and indenture. |
If
there is a continuing event of default with respect to outstanding debt securities of a series, then the trustee or the holders of not
less than 25% in aggregate principal amount of the outstanding debt securities of that series, voting as a single class, may declare
immediately due and payable the principal amount or other amount as may be specified by the terms of those debt securities and any premium
or make-whole amount on the debt securities of that series; provided, however, that upon the occurrence and continuation of certain defaults
related to bankruptcy or insolvency, the principal (or, if any debt securities are Original Issue Discount Securities or Indexed Securities,
such portion of the principal as may be specified in the terms thereof) of, and the Make-Whole Amount, if any, on, all the outstanding
debt securities of that series and any accrued interest through the occurrence of such Event of Default, shall become due and payable
immediately, without any declaration or other act by the trustee or any other holder. However, at any time after an acceleration with
respect to debt securities of a series has been made, but before a judgment or decree for payment of the money due has been obtained
by the trustee, the holders of not less than a majority in principal amount of the outstanding debt securities of that series may cancel
the acceleration and annul its consequences if:
|
● |
we
pay or deposit with the trustee all required payments of the principal of, and any premium, make-whole amount, interest, and additional
amounts on, the applicable series of debt securities, plus fees, expenses, disbursements and advances of the trustee; and |
|
|
|
|
● |
all
events of default, other than the nonpayment of accelerated principal, premium, or interest, with respect to the applicable series
of debt securities have been cured or waived as provided in the indentures. |
The
indentures also provide that the holders of not less than a majority in principal amount of the outstanding debt securities of any series
may waive any past default with respect to that series and its consequences (except in respect of certain events of default related to
bankruptcy or insolvency, the waiver of which requires approval of a majority in principal amount of all outstanding debt securities
under the applicable indenture), except a default involving:
|
● |
our
failure to pay the principal of, and any premium, make-whole amount, interest or additional amounts on, any debt security; or |
|
|
|
|
● |
a
covenant or provision contained in the applicable indenture that cannot be modified or amended without the consent of the holders
of each outstanding debt security affected by the default. |
The
trustee is generally required to give notice to the holders of debt securities of each affected series within 90 days of a default actually
known to a Responsible Officer of the trustee unless the default has been cured or waived. The trustee may, however, withhold notice
of default if the Responsible Officers of the trustee in good faith determine that the withholding of such notice is in the interests
of the holders of the debt securities of that series unless the default relates to:
|
● |
our
failure to pay the principal of, and any premium, make-whole amount, interest or additional amounts on, any debt security of that
series; or |
|
|
|
|
● |
any
sinking fund installment for any debt securities of that series. |
Each
indenture provides that no holder of debt securities of any series may institute a proceeding with respect to the indenture or for any
remedy under the indenture, unless the trustee fails to act for 60 days after it has received a written notice of a continuing event
of default with respect to the debt securities of that series from such holder and a written request to institute proceedings in respect
of an event of default from the holders of not less than 25% in principal amount of the outstanding debt securities of that series (except
in respect of certain events of default related to bankruptcy or insolvency, which requires the written request of not less than 25%
in principal amount of all outstanding debt securities under the applicable indenture), as well as an offer of indemnity satisfactory
to the trustee; provided, that no direction inconsistent with such request has been given to the trustee during such 60-day period by
the holders of a majority in principal amount of outstanding debt securities of that series. This provision will not prevent,
however, any holder of debt securities from instituting suit for the enforcement of payment of the principal of, and any premium, make-whole
amount, interest or additional amounts on, the debt securities at their respective due dates.
Subject
to provisions in each indenture relating to the trustee’s duties in case of default, the trustee is not under an obligation to
exercise any of its rights or powers under the indenture at the request or direction of any holders of any series of debt securities
then outstanding, unless the holders have offered to the trustee security or indemnity satisfactory to it. Subject to these
provisions for the indemnification of the trustee, the holders of not less than a majority in principal amount of all outstanding debt
securities under the applicable indenture will have the right to direct the time, method and place of conducting any proceeding for any
remedy available to the trustee, or of exercising any trust or power conferred upon the trustee. The trustee may, however, refuse to
follow any direction which conflicts with any law or the applicable indenture, which may involve the trustee in personal liability or
which may be unduly prejudicial to the holders of debt securities of the applicable series not joining in the direction.
Within
120 days after the close of each fiscal year, we must deliver to the trustee a certificate, signed by one of several specified officers,
stating that officer’s knowledge of our compliance with all the conditions and covenants under the applicable indenture, and, in
the event of any noncompliance, specifying the noncompliance and the nature and status of the noncompliance.
Modification
of the Indentures
Modification
Without Consent of the Holders
Together
with the trustee, we may, when authorized by our Board of Directors, modify each of the indentures without the consent of any holder
of debt securities for any of the following purposes:
|
● |
to
evidence the succession of another person to us as obligor under the indenture; |
|
|
|
|
● |
to
add to our existing covenants additional covenants for the benefit of the holders of all or any series of debt securities, or to
surrender any right or power conferred upon us in the indenture; |
|
|
|
|
● |
to
add events of default for the benefit of the holders of all or any series of debt securities; |
|
|
|
|
● |
to
add or change any provisions of the indenture to facilitate the issuance of, or to liberalize the terms of, debt securities in bearer
form, or to permit or facilitate the issuance of debt securities in uncertificated form, provided that this action will not adversely
affect the interests of the holders of the debt securities of any series in any material respect; |
|
|
|
|
● |
to
add, change or eliminate any provisions of the indenture, provided that any addition, change or elimination shall neither apply to
any debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of such
provision nor modify the rights of the holder of any debt security with respect to such provision or become effective only when there
are no outstanding debt securities; |
|
|
|
|
● |
to
secure previously unsecured debt securities; |
|
|
|
|
● |
to
establish the form or terms of debt securities of any series, including the provisions and procedures, if applicable, for the conversion
or exchange of the debt securities into our shares of common stock or other securities or property; |
|
|
|
|
● |
to
evidence and provide for the acceptance or appointment of a successor trustee or facilitate the administration of the trusts under
the indenture by more than one trustee; |
|
|
|
|
● |
to
make any provision with respect to the conversion or exchange of rights of holders pursuant to the requirements of the indenture; |
|
|
|
|
● |
to
cure any ambiguity, defect or inconsistency in the indenture, provided that the action does not adversely affect the interests of
holders of debt securities of any series issued under the indenture; |
|
|
|
|
● |
to
close the indenture with respect to the authentication and delivery of additional series of debt securities or to qualify, or maintain
qualification of, the indenture under the Trust Indenture Act; or |
|
|
|
|
● |
to
supplement any of the provisions of the indenture to the extent necessary to permit or facilitate defeasance and discharge of any
series of debt securities, provided that the action shall not adversely affect the interests of the holders of the debt securities
of any series in any material respect. |
Modification
With Consent of Holders
Together
with the trustee, we may, when authorized by our Board of Directors, also make modifications and amendments to each indenture with the
consent of the holders of a majority in principal amount of the outstanding debt securities of all affected series. Without the consent
of each affected holder, however, no modification to either indenture may:
|
● |
change
the stated maturity of the principal of, or any premium, make-whole amount or installment of principal of, or interest on, any debt
security; |
|
|
|
|
● |
reduce
the principal amount of, or the rate or amount of interest on, or any premium or make-whole amount payable on redemption of, or any
additional amounts payable with respect to, any debt security or change any obligation to pay additional amounts except as permitted
by the indenture; |
|
|
|
|
● |
reduce
the amount of principal of an original issue discount security or make-whole amount that would be due and payable upon declaration
of acceleration of the maturity of the original discount or other security, or would be provable in bankruptcy, or adversely affect
any right of repayment of the holder of any debt security; |
|
|
|
|
● |
change
the place of payment or the currency or currencies of payment of the principal of, and any premium, make-whole amount, interest,
or additional amounts on, any debt security; |
|
|
|
|
● |
impair
the right to institute suit for the enforcement of any payment on or with respect to any debt security; |
|
|
|
|
● |
reduce
the percentage of the holders of outstanding debt securities of any series necessary to modify or amend the indenture, to waive compliance
with provisions of the indenture or defaults and their consequences under the indenture, or to reduce the quorum or voting requirements
contained in the indenture; |
|
|
|
|
● |
make
any change that adversely affects the right to convert or exchange any debt security other than as permitted by the indenture or
decrease the conversion or exchange rate or increase the conversion or exchange price of any such debt security; or |
|
|
|
|
● |
modify
any of the foregoing provisions or any of the provisions relating to the waiver of past defaults or covenants, except to increase
the required percentage of holders necessary to effect that action or to provide that other provisions may not be modified or waived
without the consent of the holder of the debt security. |
Documentation
Any
modification or amendment of an indenture, whether effected with or without the consent of any holder, will be documented in a supplemental
indenture.
Discharge,
Defeasance and Covenant Defeasance
Unless
the terms of a series of debt securities provide otherwise, under the indentures, we may discharge some of our respective obligations
to holders of any series of debt securities that:
|
● |
have
not already been delivered to the trustee for cancellation and that either have become due and payable or will become due and payable
within one year; or |
|
|
|
|
● |
are
scheduled for redemption within one year. |
We
can discharge these obligations by irrevocably depositing with the trustee funds in the currency or currencies in which the debt securities
are payable in an amount sufficient to pay and discharge the entire indebtedness on those debt securities, including principal of, and
any premium, make-whole amount, interest and additional amounts on, the debt securities on and up to the date of such deposit, or, if
the debt securities have become due and payable, on and up to the stated maturity or redemption date, as the case may be.
In
addition, if the terms of the debt securities of a series permit us to do so, we may elect either of the following:
|
● |
to
defease and be discharged from any and all obligations with respect to the debt securities, except, among other things, our obligations
to the holders of Outstanding Securities; |
|
|
|
|
● |
pay
any additional amounts upon the occurrence of several particular tax and other events; |
|
|
|
|
● |
pay
the fees, expenses and indemnitees of the trustee; |
|
● |
register
the transfer or exchange of the debt securities; |
|
|
|
|
● |
replace
temporary or mutilated, destroyed, lost or stolen debt securities; |
|
|
|
|
● |
maintain
an office or agency for the debt securities; and |
|
|
|
|
● |
hold
monies for payment in trust; or |
|
|
|
|
● |
to
be released from our obligations with respect to the debt securities under sections of the applicable indenture described under “Certain
Covenants” or, if permitted by the terms of the debt securities, our obligations with respect to any other covenant. |
If we choose to be released from
our respective obligations under the covenants, any failure to comply with any of the obligations imposed on us by the covenants will
not constitute a default or an event of default with respect to the debt securities. However, to make either election, we must irrevocably
deposit with the trustee an amount, in such currency or currencies in which the debt securities are payable at their stated maturity,
or in Government Obligations, or both, that will provide sufficient funds to pay the principal of, and any premium, make-whole amount,
interest and additional amounts on, the debt securities, and any mandatory sinking fund or similar payments on the debt securities, on
the relevant scheduled due dates.
We
may defease and discharge the obligations, as described in the preceding paragraphs, only if, among other things, we have delivered to
the trustee an opinion of counsel to the effect that:
|
● |
the
holders of the debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the defeasance
or covenant defeasance described in the previous paragraphs and will be subject to U.S. federal income tax on the same amounts, in
the same manner and at the same times as would have been the case if the defeasance or covenant defeasance had not occurred; and |
|
|
|
|
● |
in
the case of defeasance, the opinion of counsel must refer to, and be based upon, a ruling of the Internal Revenue Service, or IRS,
or a change in applicable U.S. federal income tax laws occurring after the date of the applicable indenture. |
Unless
otherwise provided in the applicable prospectus supplement, if, after we have deposited funds and/or Government Obligations to effect
defeasance or covenant defeasance with respect to debt securities of any series:
|
● |
the
holder of a debt security of the series elects to receive payment in a currency other than that in which the deposit has been made
in respect of the debt security; or |
|
|
|
|
● |
a
conversion event, as defined below, occurs in respect of the currency in which the deposit has been made, |
then
the indebtedness represented by the debt security will be fully discharged and satisfied through the payment of the principal of, and
any premium, make-whole amount and interest on, the debt security as they become due, and additional amounts, if any, out of the proceeds
yielded by converting the amount deposited in respect of the debt security into the currency in which the debt security becomes payable
as a result of the holder’s election or the conversion event based on the applicable market exchange rate.
Unless
otherwise provided in the applicable prospectus supplement, a “conversion event” means the cessation of use of:
|
● |
a
currency issued by the government of one or more countries other than the United States, both by the government of the country that
issued that currency and for the settlement of transactions by a central bank or other public institutions of or within the international
banking community; |
|
|
|
|
● |
the
European Community, both within the European Monetary System and, for the settlement of transactions, by public institutions of or
within the European Community; or |
|
|
|
|
● |
any
currency for the purposes for which it was established. |
Unless
otherwise provided in the applicable prospectus supplement, we will make all payments of principal of, and any premium, make-whole amount,
interest and additional amounts on, any debt security that is payable in a foreign currency that ceases to be used by its government
of issuance in United States dollars.
In
the event that we effect covenant defeasance with respect to any debt securities and the debt securities are declared due and payable
because of the occurrence of an event of default other than:
|
● |
the
event of default described in the fourth bullet under “Certain Covenants—Events of Default, Notice and Waiver,”
which would no longer be applicable to the debt securities of that series; or |
|
|
|
|
● |
the
event of default described in the sixth bullet under “Certain Covenants—Events of Default, Notice and Waiver” with
respect to a covenant as to which there has been covenant defeasance, |
then
the amount on deposit with the trustee will still be sufficient to pay amounts due on the debt securities at the time of their stated
maturity but may not be sufficient to pay amounts due on the debt securities at the time of the acceleration resulting from the event
of default. In this case, we would remain liable to make payment of the amounts due at the time of acceleration.
The
applicable prospectus supplement may describe any additional provisions permitting defeasance or covenant defeasance, including any modifications
to the provisions described above, with respect to a particular series of debt securities.
Conversion
and Exchange Rights
The
terms on which debt securities of any series may be convertible into or exchangeable for our shares of common stock or other securities
or property will be described in the applicable prospectus supplement. These terms will include:
|
● |
the
conversion or exchange price, or the manner of calculating the price; |
|
|
|
|
● |
the
exchange or conversion period; |
|
|
|
|
● |
whether
the conversion or exchange is mandatory, or voluntary at the option of the holder or at our option; |
|
|
|
|
● |
any
restrictions on conversion or exchange in the event of redemption of the debt securities and any restrictions on conversion or exchange;
and |
|
|
|
|
● |
the
means of calculating the number of shares of our shares of common stock or other securities or property of us to be received by the
holders of debt securities. |
The
conversion or exchange price of any debt securities of any series that are convertible into our shares of common stock, may be adjusted
for any stock dividends, stock splits, reclassification, combinations or similar transactions, as set forth in the applicable prospectus
supplement (Article Sixteen).
Governing
Law
The
indentures will be governed by the laws of the State of New York.
Redemption
of Debt Securities
The
debt securities may be subject to optional or mandatory redemption on terms and conditions described in the applicable prospectus supplement.
Subject to such terms, we may opt at any time to partially or entirely redeem the debt securities.
From
and after notice has been given as provided in the applicable indenture, if funds for the redemption of any debt securities called for
redemption shall have been made available on the redemption date, the debt securities will cease to bear interest on the date fixed for
the redemption specified in the notice, and the only right of the holders of the debt securities will be to receive payment of the redemption
price.
DESCRIPTION
OF WARRANTS
We
may issue and offer warrants under the material terms and conditions described in this prospectus and any accompanying prospectus supplement.
The accompanying prospectus supplement may add, update or change the terms and conditions of the warrants as described in this prospectus.
We
may issue warrants to purchase shares of common stock, preferred stock and/or debt securities in one or more series. Warrants may be
issued independently or together with any other securities and may be attached to, or separate from, such securities. Each series of
warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent. The warrant agent will
act solely as our agent and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants.
The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth
in the applicable prospectus supplement.
The
applicable prospectus supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:
|
● |
the
title of such warrants; |
|
|
|
|
● |
the
aggregate number of such warrants; |
|
|
|
|
● |
the
price or prices at which such warrants will be issued and exercised; |
|
|
|
|
● |
the
currency or currencies in which the price of such warrants will be payable; |
|
|
|
|
● |
the
securities purchasable upon exercise of such warrants; |
|
|
|
|
● |
the
date on which the right to exercise such warrants shall commence and the date on which such right shall expire; |
|
|
|
|
● |
if
applicable, the minimum or maximum amount of such warrants which may be exercised at any one time; |
|
|
|
|
● |
if
applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued
with each such security; |
|
|
|
|
● |
if
applicable, the date on and after which such warrants and the related securities will be separately transferable; |
|
|
|
|
● |
information
with respect to book-entry procedures, if any; |
|
|
|
|
● |
material
Israeli and United States federal income tax consequences, if any; |
|
|
|
|
● |
the
anti-dilution provisions of the warrants, if any; and |
|
|
|
|
● |
any
other terms of such warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants. |
The
description in the applicable prospectus supplement of any warrants we offer will not necessarily be complete and will be qualified in
its entirety by reference to the applicable warrant agreement and warrant certificate, which will be filed with the SEC if we offer warrants.
For more information on how you can obtain copies of the applicable warrant agreement and warrant certificate if we offer warrants, see
“Where You Can Find More Information” and “Incorporation of Certain Documents by Reference” beginning on page
33. We urge you to read the applicable warrant agreement and warrant certificate and any applicable prospectus supplement in their
entirety.
DESCRIPTION
OF UNITS
We
may issue units comprised of one or more of the other securities that may be offered under this prospectus, in any combination. Each
unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit
will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide
that the securities included in the unit may not be held or transferred separately at any time, or at any time before a specified date.
The
prospectus supplement relating to any units we offer will, to the extent applicable, include specific terms relating to the offering,
including some or all of the following:
|
● |
the
material terms of the units and of the securities comprising the units, including whether and under what circumstances those securities
may be held or transferred separately; |
|
|
|
|
● |
any
material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising
the units; and |
|
|
|
|
● |
any
material provisions of the governing unit agreement that differ from those described above. |
The
description in the applicable prospectus supplement of any units we offer will not necessarily be complete and will be qualified in its
entirety by reference to the applicable unit agreement, which will be filed with the SEC if we offer units. For more information on how
you can obtain copies of the applicable unit agreement if we offer units, see “Where You Can Find More Information” and “Incorporation
of Certain Documents by Reference” beginning on page 33. We urge you to read the applicable unit agreement and any applicable
prospectus supplement in their entirety.
FORMS
OF SECURITIES
Each
debt security and, to the extent applicable, warrant, subscription right and unit, will be represented either by a certificate issued
in definitive form to a particular investor or by one or more global securities representing the entire issuance of securities. Certificated
securities in definitive form and global securities will be issued in registered form. Definitive securities name you or your nominee
as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other
interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent,
as applicable. Global securities name a depositary or its nominee as the owner of the debt securities or warrants represented by these
global securities. The depositary maintains a computerized system that will reflect each investor’s beneficial ownership of the
securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain
more fully below.
Global
Securities
Registered
Global Securities. We may issue the registered debt securities and, to the extent applicable, warrants, subscription rights and units,
in the form of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the
applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global
securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount
of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive
registered form, a registered global security may not be transferred except as a whole by and among the depositary for the registered
global security, the nominees of the depositary or any successors of the depositary or those nominees.
If
not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered
global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions
will apply to all depositary arrangements.
Ownership
of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the
depositary or persons that may hold interests through participants. Upon the issuance of a registered global security, the depositary
will credit, on its book-entry registration and transfer system, the participants’ accounts with the respective principal or face
amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution
of the securities will designate the accounts to be credited. Ownership of beneficial interests in a registered global security will
be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect
to interests of participants, and on the records of participants, with respect to interests of persons holding through participants.
The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form.
These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities.
So
long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the
case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes
under the applicable indenture or warrant agreement. Except as described below, owners of beneficial interests in a registered global
security will not be entitled to have the securities represented by the registered global security registered in their names, will not
receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders
of the securities under the applicable indenture or warrant agreement. Accordingly, each person owning a beneficial interest in a registered
global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant,
on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable
indenture or warrant agreement. We understand that under existing industry practices, if we request any action of holders or if an owner
of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take
under the applicable indenture or warrant agreement, the depositary for the registered global security would authorize the participants
holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning
through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them.
Principal,
premium, if any, interest payments on debt securities and any payments to holders with respect to warrants represented by a registered
global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may
be, as the registered owner of the registered global security. None of the Company, the trustees, the warrant agents or any other agent
of the Company, the trustees or the warrant agents will have any responsibility or liability for any aspect of the records relating to
payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing
any records relating to those beneficial ownership interests.
We
expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment of principal,
premium, interest or other distribution of underlying securities or other property to holders on that registered global security, will
immediately credit participants’ accounts in amounts proportionate to their respective beneficial interests in that registered
global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests
in a registered global security held through participants will be governed by standing customer instructions and customary practices,
as is now the case with the securities held for the accounts of customers in bearer form or registered in “street name,”
and will be the responsibility of those participants.
If
the depositary for any of these securities represented by a registered global security is at any time unwilling or unable to continue
as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing
agency under the Exchange Act is not appointed by us within 90 days, we will issue securities in definitive form in exchange for the
registered global security that had been held by the depositary. Any securities issued in definitive form in exchange for a registered
global security will be registered in the name or names that the depositary gives to the relevant trustee or warrant agent or other relevant
agent of ours or theirs. It is expected that the depositary’s instructions will be based upon directions received by the depositary
from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary.
PLAN
OF DISTRIBUTION
We
may sell the securities described in this prospectus from time to time in one or more of the following ways:
|
● |
through
agents; |
|
|
|
|
● |
to
or through one or more underwriters on a firm commitment or agency basis; |
|
|
|
|
● |
through
put or call option transactions relating to the securities; |
|
|
|
|
● |
to
or through dealers, who may act as agents or principals, including a block trade (which may involve crosses) in which a broker or
dealer so engaged will attempt to sell as agent but may position and resell a portion of the block as principal to facilitate the
transaction; |
|
|
|
|
● |
through
privately negotiated transactions; |
|
|
|
|
● |
purchases
by a broker or dealer as principal and resale by such broker or dealer for its own account pursuant to this prospectus; |
|
|
|
|
● |
directly
to purchasers, including our affiliates, through a specific bidding or auction process, on a negotiated basis or otherwise; to or
through one or more underwriters on a firm commitment or best efforts basis; |
|
|
|
|
● |
exchange
distributions and/or secondary distributions; |
|
|
|
|
● |
ordinary
brokerage transactions and transactions in which the broker solicits purchasers; |
|
|
|
|
● |
in
an “at the market offering”, within the meaning of Rule 415(a)(4) of the Securities into an existing trading market,
on an exchange or otherwise; |
|
|
|
|
● |
transactions
not involving market makers or established trading markets, including direct sales or privately negotiated transactions; |
|
|
|
|
● |
transactions
in options, swaps or other derivatives that may or may not be listed on an exchange; |
|
|
|
|
● |
through
any other method permitted pursuant to applicable law; or |
|
|
|
|
● |
through
a combination of any such methods of sale. |
At
any time a particular offer of the securities covered by this prospectus is made, a revised prospectus or prospectus supplement, if required,
will be distributed which will set forth the aggregate amount of securities covered by this prospectus being offered and the terms of
the offering, including the name or names of any underwriters, dealers, brokers or agents, any discounts, commissions, concessions and
other items constituting compensation from us and any discounts, commissions or concessions allowed or re-allowed or paid to dealers.
Such prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this prospectus is a
part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution of the securities
covered by this prospectus. In order to comply with the securities laws of certain states, if applicable, the securities sold under this
prospectus may only be sold through registered or licensed broker-dealers. In addition, in some states the securities may not be sold
unless they have been registered or qualified for sale in the applicable state or an exemption from registration or qualification requirements
is available and is complied with.
The
distribution of securities may be effected from time to time in one or more transactions, including block transactions and transactions
on the Nasdaq Capital Market or any other organized market where the securities may be traded. The securities may be sold at a fixed
price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market
prices or at negotiated prices. The consideration may be cash or another form negotiated by the parties. Agents, underwriters or broker-dealers
may be paid compensation for offering and selling the securities. That compensation may be in the form of discounts, concessions or commissions
to be received from us or from the purchasers of the securities. Any dealers and agents participating in the distribution of the securities
may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts.
If any such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.
Agents
may from time to time solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement any
agent involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated
in the prospectus supplement, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the
securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.
To
the extent that we make sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to
the terms of a distribution agreement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution
agreement, we will sell any of our listed securities to or through one or more underwriters or agents, which may act on an agency basis
or on a principal basis. During the term of any such agreement, we may sell any of our listed securities on a daily basis in exchange
transactions or otherwise as we agree with the underwriters or agents. The distribution agreement will provide that any of our listed
securities which are sold will be sold at prices related to the then prevailing market prices for our listed securities. Therefore, exact
figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time and will be described in a
prospectus supplement. Pursuant to the terms of the distribution agreement, we also may agree to sell, and the relevant underwriters
or agents may agree to solicit offers to purchase, blocks of our listed securities. The terms of each such distribution agreement will
be set forth in more detail in a prospectus supplement to this prospectus.
If
underwriters are used in a sale, securities will be acquired by the underwriters for their own account and may be resold from time to
time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter
or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities,
and will set forth the terms of the transactions, including compensation of the underwriters and dealers and the public offering price,
if applicable. The prospectus and prospectus supplement will be used by the underwriters to resell the securities.
If
a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required,
we will set forth in the prospectus supplement the name of the dealer and the terms of the transactions.
We
may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others.
These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities.
To the extent required, the prospectus supplement will describe the terms of any such sales, including the terms of any bidding or auction
process, if used.
Agents,
underwriters and dealers may be entitled under agreements which may be entered into with us to indemnification by us against specified
liabilities, including liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make
in respect of such liabilities. If required, the prospectus supplement will describe the terms and conditions of the indemnification
or contribution. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or
perform services for us or our subsidiaries.
Any
person participating in the distribution of securities registered under the registration statement that includes this prospectus will
be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation
M, which may limit the timing of purchases and sales of any of our securities by that person. Furthermore, Regulation M may restrict
the ability of any person engaged in the distribution of our securities to engage in market-making activities with respect to our securities.
These restrictions may affect the marketability of our securities and the ability of any person or entity to engage in market-making
activities with respect to our securities.
Certain
persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, penalty bids
and other transactions that stabilize, maintain or otherwise affect the price of the offered securities. These activities may maintain
the price of the offered securities at levels above those that might otherwise prevail in the open market, including by entering stabilizing
bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below:
|
● |
a
stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining
the price of a security. |
|
|
|
|
● |
a
syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase
to reduce a short position created in connection with the offering. |
|
● |
a
penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in
connection with the offering when offered securities originally sold by the syndicate member are purchased in syndicate covering
transactions. |
These
transactions may be effected on an exchange or automated quotation system, if the securities are listed on that exchange or admitted
for trading on that automated quotation system, or in the over-the-counter market or otherwise.
If
so indicated in the applicable prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain
types of institutions to purchase offered securities from us at the public offering price set forth in such prospectus supplement pursuant
to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be subject only
to those conditions set forth in the prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation
of such contracts.
In
addition, shares of common stock, preferred stock or warrants may be issued upon conversion of or in exchange for debt securities or
other securities.
Any
underwriters to whom offered securities are sold for public offering and sale may make a market in such offered securities, but such
underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The offered securities
may or may not be listed on a national securities exchange. No assurance can be given that there will be a market for the offered securities.
Any
securities that qualify for sale pursuant to Rule 144 or Regulation S under the Securities Act may be sold under Rule 144 or Regulation
S rather than pursuant to this prospectus.
In
connection with offerings made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant
to which we receive our outstanding securities in consideration for the securities being offered to the public for cash. In connection
with these arrangements, the underwriters or agents may also sell securities covered by this prospectus to hedge their positions in these
outstanding securities, including in short sale transactions. If so, the underwriters or agents may use the securities received from
us under these arrangements to close out any related open borrowings of securities.
We
may enter into derivative transactions with third parties or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, such third parties
(or affiliates of such third parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including
in short sale transactions. If so, such third parties (or affiliates of such third parties) may use securities pledged by us or borrowed
from us or others to settle those sales or to close out any related open borrowings of shares, and may use securities received from us
in settlement of those derivatives to close out any related open borrowings of shares. The third parties (or affiliates of such third
parties) in such sale transactions will be underwriters and will be identified in the applicable prospectus supplement (or a post-effective
amendment).
We
may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus.
Such financial institution or third party may transfer its short position to investors in our securities or in connection with a simultaneous
offering of other securities offered by this prospectus or in connection with a simultaneous offering of other securities offered by
this prospectus.
LEGAL
MATTERS
The
validity of the issuance of the securities offered hereby will be passed upon for us by McDermott Will & Emery LLP, New York, New
York. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the
applicable prospectus supplement.
EXPERTS
Our
financial statements as of December 31, 2021 and
2020, and for each of the years then ended, have been incorporated by reference herein in reliance upon the report of Haskell & White
LLP, independent registered public accounting firm, and upon the authority of said firm as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC’s
rules, this prospectus and any prospectus supplement, which form a part of the registration statement, do not contain all the information
that is included in the registration statement. You will find additional information about us in the registration statement. Any statements
made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the
documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding
of the document or matter.
We
are subject to the informational requirements of the Exchange Act, and, in accordance with those requirements, file annual, quarterly
and current reports, proxy statements and other information with the SEC. Such reports, proxy statements and other information, as well
as this registration statement and the exhibits and schedules thereto, are available on the SEC website at www.sec.gov. Copies of these
documents may also be accessed on our website at www.indaptusrx.com. Our internet website and the information contained therein or connected
thereto are not incorporated into this prospectus or any amendment or supplement thereto.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The
SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we
can disclose important information to you by referring you to those documents. The information incorporated by reference
is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and
supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus
or a subsequently filed document incorporated by reference modifies or replaces that statement.
This prospectus and any accompanying
prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC:
|
● |
our
Annual Report on Form 10-K for the fiscal year ended on December 31, 2021, filed with the
SEC on March 21, 2022;
|
|
|
|
|
● |
our
Quarterly Report on Form 10-Q for the quarter ended on March 31, 2022, filed with the SEC on May 12, 2022; |
|
|
|
|
● |
our Quarterly Report on Form 10-Q for the quarter ended on June 30, 2022, filed with the SEC on August 8, 2022; |
|
|
|
|
● |
our
Current Reports on Form 8-K (other than the information furnished pursuant to Item 2.02 or
7.01 thereof or related exhibits furnished pursuant to Item 9.01 thereof) filed with the
SEC on January 3, 2022, February 1, 2022, May 19, 2022, June 1, 2022 and July 21, 2022; and
|
|
|
|
|
● |
the
description of our shares of common stock contained in our Registration Statement on Form 8-A (File No. 001-40652), filed with the
SEC on July 23, 2021, including any amendment or report filed for the purpose of updating such description. |
All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act in this prospectus,
prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration
statement of which this prospectus is a part and prior to the effectiveness of the registration statement, but excluding any information
furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this
prospectus from the date of the filing of such reports and documents.
We
will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this
prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. You may request
a copy of any or all of these filings, at no cost, by writing or telephoning us at: Nir Sassi, Chief Financial Officer, 3 Columbus Circle,
15th Floor, New York, NY 10019. You may also access the documents incorporated by reference in this prospectus through our website
at www.indaputus.com. Except for the specific incorporated documents listed above, no information available on or through our website
shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part.
INDAPTUS
THERAPEUTICS, INC.
Up
to $6,300,000
Shares
of Common Stock
PROSPECTUS
SUPPLEMENT
H.C.
Wainwright & Co.
September
9, 2022
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024